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CHAPTER 1 
INTRODUCTION 
With dry compression-coating, water and other solvents in the coating procedure 
can be eliminated, moisture can be prevented from penetrating into the core, dissolution 
and disintegration of the tablet can be modified, and incompatible active ingredients can 
be separated. If a drug tends to discolor readily or tablets develop a mottled appearance 
because of oxidation or sunlight, these problems can be minimized by incorporating the 
drug into the core tablet. 
Chapters 2 and 3 of the thesis describe compression-coated tablet formulations of 
amoxicillin and clavulanic acid. The effect of separation of the two active ingredients in 
the same tablet on their stability to moisture was studied. The effect of incorporating a 
hydrophobic barrier around the core on stability of clavulanic acid in the core was also 
studied. The effects of this formulation design on drug dissolution, tablet disintegration, 
and mechanical strength of the tablet were evaluated and optimized. Based on in vitro 
results, some formulations were selected for further testing in human subjects. 2 
Chapter 4 evaluates and compares pharmacokinetic parameters of a new 
compression-coated formulation of amoxicillin/clavulanate and Augmentine, a reference 
product. Employing a randomized balanced cross over study, preliminary statistical 
pharmacokinetic analysis was done for 8 subjects. Data were analyzed by a two one-sided 
t-test. 
Many new chemical entities with promising pharmacological activity never make 
it through clinical trials because their solubility is so low that a useful drug delivery 
system can not be developed for them. Emulsions are used effectively to enhance 
dissolution and bioavailability of hydrophobic drugs and to prevent their precipitation at 
the site of injection upon parenteral administration. To produce a stable emulsion, 
relatively large amounts of surfactants are needed, which might have systemic toxicity, 
such as gastrointestinal irritation and erythrocyte hemolysis. Nisin is a highly surface 
active cationic polyp eptide with antimicrobial activity. It can withstand activity loss 
during thermal processing, and exposure to acidic environments. These characteristics 
and others, such as non-toxicity and surface activity, make its potential as an 
antimicrobial emulsifier attractive in pharmaceutical emulsions. 
In Chapter 6, an emulsion conductivity apparatus was used to evaluate the 
emulsifying activity of nisin as a function of concentration and pH by measuring 
emulsion stability. For control purposes, all experiments were repeated using Tween® 80 
and 13-casein in place of nisin. Image analysis was used to measure particle size and to 
characterize emulsion structures. 
In Chapter 7, a DuNouy tensiometer was used to determine how concentration 
and time affect interfacial activity of nisin at an oil-water interface. Interfacial tension 3 
kinetic data were interpreted with reference to models that allow for nisin to unfold 
before and after adsorption. 
In chapter 8, the effects of nisin on drug release in oil-in-water emulsions, and red 
blood cells were investigated. 4 
CHAPTER 2 
MULTIPLE LAYER COMPRESSION-COATED FORMULATIONS
 
OF AMOXICILLIN AND CLAVULANIC ACID CHEWABLE
 
TABLET
 5 
ABSTRACT 
Two compression-coated chewable tablet formulations have been developed for 
amoxicillin and clavulanic acid. The two active ingredients are relatively unstable, 
particularly clavulanic acid which is rapidly degraded by moisture. Stability of the two 
active ingredients has been studied in both formulations at room temperature at 96% and 
45% relative humidity. Results were compared to those obtained from the marketed 
formulation and other three formulations which represent a combination of ingredients of 
the various layers of the compression-coated tablet, but intimately mixed and compressed 
into a single layer tablet. It has been found that separation of the two active ingredients 
contributes to enhance the stability of the two active ingredients. The stability of 
clavulanic acid was optimized by addition of stearic acid into the middle layer of a 
compression-coated tablet. The dissolution profile of the two active ingredients from the 
compression-coated tablet was found to be quite different from that of the conventional 
marketed formulation. This difference is due to the design of the compression-coated 
tablet. However, both formulations met the USP requirements for dissolution. 6 
INTRODUCTION
 
Compression-coating tablet consists of a core, on which one or two coats are 
compressed. The core is formulated as an ordinary tablet using compression or 
granulation techniques (1). Coating formulations, on the other hand, have some special 
requirements so that they will make a physically stable tablet (1). They require excellent 
cohesiveness as well as the ability to adhere to the core. They should be plastic enough to 
expand slightly with the slight swelling of the core after extrusion of the completed tablet 
from the die. The maximum size of the granules must be less than the space between the 
deposited core and the walls of the die so that the granules will readily fill the space. 
Unlike other coating procedures, such as sugar coating, which may increase a tablet 
weight by 50-100% of the core weight, compression-coating requires a coat which is 
about twice the weight of the core (1). 
With compression-coating, incompatible substances can be separated by placing 
one of them in the core and the other in the coating (1). In addition, if a drug tends to 
discolor readily or develop a mottled appearance because of oxidation or sunlight, these 
can be minimized by incorporating the drug in the core tablet (1). 
Amoxicillin and clavulanic acid are available as a fixed combination of 
amoxicillin trihydrate and potassium salt of clavulanic acid in the product Augmentin®. 
Amoxicillin (a-amino-p-hydroxybenzyl ampicillin) is a semisynthetic penicillin (2). 
Clavulanic  acid  (Z-(2R,5R)-3-(13-hydorxyethyledine)-7-oxo-1-azobicyclo- [3 .2.0]­
heptane-2-carboxylic acid) is a potent inhibitor of the enzyme 13-lactamase produced by a 
variety of Gram positive and Gram negative bacteria (2). Clavulanic acid, however, 
exhibits only weak antibacterial activity and is therefore unsuitable for use alone (2). The 7 
combination of amoxicillin and potassium clavulanate is active against many 13-lactamase 
producing bacteria which are resistant to amoxicillin alone because clavulanic acid 
inhibits 13-lactamase (2). 
Amoxicillin/potassium  clavulanate  is  commercially  available  for  oral 
administration as film-coated tablets containing a 2:1 or 4:1 ratio of amoxicillin to 
clavulanic acid, or as a powder for oral suspension or chewable tablets containing a 4:1 
ratio of the drugs (2). Commercially available amoxicillin and potassium clavulanate film 
coated tablets, chewable tablets, and powder for oral suspension should be stored in air 
tight containers at a temperature less than 24 °C; exposure to excessive light should be 
avoided (2). Following reconstitution, oral suspensions of amoxicillin and potassium 
clavulanate should be stored at 2-8°C, and any unused suspension should be discarded 
after 10 days (2). 
The objective of this project is to develop a novel triple compression-coated tablet 
formulation of amoxicillin/potassium clavulanate. A schematic design of the formulation 
is shown in Figure 2.1. Both amoxicillin trihydrate and potassium clavulanic acid degrade 
quickly in solution and the later, in particular, is extremely moisture sensitive and readily 
discolors (3,4). Potassium clavulanate was formulated as a core tablet, on which two 
further coats have been compressed. The center layer consists of inert materials which 
provide complete separation of the two active ingredients. The outer layer contains 
amoxicillin trihydrate. The destabilization effect of moisture and light on clavulanic acid 
in the core can be minimized by the two outer coats. 8 
Figure 2.1. Schematic representation of compression-coated tablet. 
Center layer 
Core 
Outer layer 
MATERIALS 
Amoxicillin trihydrate (lot # 6453-X5), potassium clavulanate-Avicel mixture (lot 
# CkA-91), mannitol granular form (lot # B4199), magnesium stearate (lot # TB4236), 
and sodium saccharin (lot # B4073) were obtained from Biocraft Lab., Fairfield, NJ. 
Stearic acid powder (triple pressed) (lot # F50335) was from J.T Baker, Philipsburg, NJ. 
Ac-Di-Sol® (modified cellulose gum) (lot # T325) was from FMC, Newark, DE. D&C 
Yellow # 10 was from Warner Jenkinson Co., St Louis, MO. Artificial banana flavor was 
from Robert Flavors, South plain Field, NJ. 9 
METHODS
 
Tablet manufacture 
Two compression-coated formulations and three conventional single layer 
formulations were prepared to study the effect of compression-coated tablet design on the 
stability of amoxicillin and clavulanic acid, and to achieve a suitable formulation for 
further dissolution and bioavailability studies. These formulations are based on the 
composition of four powder mixtures. The compositions of these mixtures are illustrated 
in Table 2.1. 
Mixtures #1, #2, and #3 were prepared by mixing ingredients in a plastic bottle 
for five minutes with a spatula. Each resulting mixture was passed through a 40 mesh 
sieve. All ingredients of mixture #3, except mannitol, were mixed well in a plastic bottle 
for 5 minutes and were sieved through a 40 mesh sieve. Mannitol was added and mixed 
for 5 minutes to give the final mixture. Mannitol in granular form (direct compression 
grade) was added last because its granular size was too big to pass through a 40 mesh 
sieve. Formulations #1 and #2 (Table 2.2) are compression-coated chewable tablets 
consisting of the same core and outer layer. However, the middle layer consists of stearic 
acid and Avicel (1:1 mixture) Plus Ac-Di-sol in Formulation #1, or of Avicel plus Ac-Di-
Sol in Formulation #2. The purpose of these two formulations is to study the effect of 
stearic acid as a hydrophobic barrier when incorporated in the middle layer on the 
stability of clavulanic acid. 10 
1 
Table 2.1. Composition of four mixtures used in different combinations to prepare five 
formulations of amoxicillin and clavulanic acid. 
Mixture #	  Ingredient 
Clavulanic acid 
Mg-stearate 
Ac-Di-Sol 
Avicel PH 112 
Stearic acid 
Ac-Di-Sol 
Avicel PH 112 
Ac-Di-Sol 
Amoxicillin 
Avicel PH 112 
Mannitol 
Mg-stearate 
Na-Saccharine 
Banana flavor 
C&D yellow 
Amount per tablet (mg) 
171.2 
2.5 
7.5 
50 
50 
5.0 
100 
5.0 
230 
200 
200 
5.0 
5.0 
3.0 
0.5 11 
Table 2.2. Type and composition of five tested formulations based on mixtures inTable 
2.1. 
Formulation #  Formulation  Mixture #1  Mixture #2  Mixture #3  Mixture #4 
type  (mg)  (mg)  (mg)  (mg) 
1  Compression-
Coated 
Core  181.2 
Middle layer  105 
Outer layer  743 
2  Compression-
Coated 
Core  181.5 
Middle layer  105 
Outer layer  743 
3  Conventional  181.2  105  743 
4  Conventional  181.2  105  743 
5  Conventional  181.2  743 12 
Formulations #3, #4, and #5 (Table 2.2) are conventional single layer tablets. 
Formulation #3 and #4 were prepared form the ingredients combining the core, middle 
layer, and outer layer of Formulations #1 and #2, respectively. Formulation #5 is a 
combination of the core and the outer layer of Formulation #1 into a single layer tablet. 
The effect of compression-coated formulation on stability of amoxicillin and 
clavulanic acid can be evaluated by comparing the stability of Formulations #1 and #2 
with those of Formulations #3, #4, and #5. 
The following procedure was followed in manufacturing Formulations #1 and #2 
1. Core 
A circular die of 1.1 cm diameter was filled manually with the powder mixture of the 
core and compressed at 1000 lb using a carver press (Fred S. Carver Inc., Summit, New 
Jersey). 
2. Precompressed core and middle layer 
About half of the mixture of ingredients for the center layer was added into a circular die 
of 1.26 cm diameter. The precompressed core was placed in the middle of the die. The 
second half of the mixture was added. The mixture with the core inside was compressed 
manually using a small hand held Vankel press (the exact compression force cannot be 
determined but it was less than 1000 lb). 
3. Final tablet 
The mixture of ingredients of the outer layer was compressed around the center layer 
(from step 2 above) in the same way as previously described using a 1.59 cm wide 
circular die and 6000 lb to produce the final tablet. 13 
For Formulations #3, #4 and #5, the appropriate amounts of ingredients of each 
formulation were combined and mixed well for 5 minutes. The final mixture was 
compressed in the same die used in preparation of the final compression-coated tablets at 
6000 lb. 
Stability studies 
The tablets of formulations described above were subjected to 96% and 45% 
relative humidity at ambient temperature for 4 days and 30 days, respectively. Standard 
all glass aquariums (50 cm long, 26 cm wide, 30 cm high) with plastic cover were used as 
humidity tanks. Saturated solutions of calcium sulfate trihydrate (provided 96% relative 
humidity) and potassium carbonate anhydrous (provided 46% relative humidity) were 
prepared and placed in the bottom of the tanks. 
A plastic rack was placed in the tank to hold petri dishes 7 cm above the surface 
of the saturated solution. Humidity was monitored using a wet and dry bulb (Mason type) 
hygrometer. 
At 97% relative humidity, tablets were removed for determination of amount of 
intact amoxicillin and clavulanic acid at 6, 12, 24, 36, 48, 60, 72, and 90 hours. Time 
intervals for amoxicillin and clavulanic acid assay at 45% relative humidity were 1, 3, 5, 
7, 9, 11, 13, 15, 20, 25, and 30 days. At each time interval, three tablets of each 
formulation were assayed for amoxicillin and clavulanic acid content. Each tablet was 
powdered using a mortar and pestle and the powder was transferred into a 400 ml beaker. 
100 ml deionized water was used to rinse the mortar to remove any remaining powder 
before making up to 500 ml volume. The mixture in the beaker was stirred for 45 minutes 14 
and duplicate 1 ml samples were taken from each beaker. Each sample was diluted with 
10 ml distilled water and the solution was vortexed to ensure mixing before preparation 
of the samples for analysis. A sensitive HPLC method with UV detection (5) was used to 
assess drug stability 
Assessment of formulations 
Good flow properties of powders are critical for an efficient tableting operation. 
When a heap of powder is allowed to stand with only gravitational force acting on it, the 
angle ,between the free surface of the heap and the horizontal  can achieve a certain 
maximum for a given powder. This angle is the angle of repose. It was measured for each 
layer of the powder mixture. The powder was poured through a wide neck funnel and the 
circular fall pattern traced on paper. The diameter of this circle was measured several 
times and the mean radius value (r) obtained. The height of the powder pile (h)  was 
measured and the angle of repose (a) was calculated from the following equation (6): 
Tan a =  hlr 
Measurements were made in triplicate for tablets, including the  core and middle layer 
tablet. 
Hardness of the core, middle layer, and outer layer was determined by a strong 
Cobb tablet hardness tester. An average of three readings was taken as the final hardness. 
Recommended hardness limits are greater than 5 kg, although chewable tablets may be 
somewhat softer (6). 15 
For friability testing, 6 dedusted tablets were weighed, and placed in the 
laboratory friability tester (VankelKamp). The friabiliator  were operated for 100 
revolutions. The tablets were dedusted and reweighed. 
According to the USP weight variation test, 20 tablets were weighed individually. 
The mean weight was calculated. The number of tablets outside the 5% limit  was 
determined. 
Disintegration 
The USP Device with 6 glass tubes 3 inches long,  open at the top, and held 
against a 10 mesh screen at the bottom end of the basket assembly  was used to test 
disintegration. A total of 6 tablets were placed in the apparatus positioned in a 1 L beaker 
of water at 37 °C. A standard motor device was used to move the assembly containing the 
tablets up and down at a frequency of 29 cycle per minute. 
Dissolution 
Dissolution tests were conducted according to the USP )0C II paddle methodat 37 
° C, 75 rpm. Dissolution media consisted of 900 ml deionized water. The dissolution 
profile was determined in triplicate for 50 minutes. 5 ml samples drawn via syringe with 
inline stone filter (2 micron immersible HPLC mobile phase filter, Alltech)  were 
collected at 6, 12, 20, 30, 40, and 50 minutes with replacement of equal volume of 
deionized water. Amount of each drug released was measured separately using HPLC (5). 
The undiluted withdrawn solution was used for measuring the amount of clavulanic acid 16 
released, while 1 ml of this solution was diluted with 5 ml deionized water to give  a 
suitable concentration of amoxicillin to be injected into the HPLC. 
RESULTS AND DISCUSSION 
Stability 
Figures 2.2 and 2.3 show that clavulanic acid in Formulation #1 is much more 
stable at room temperature than clavulanic acid in the marketed formulation and other 
tested formulations. The most stable formulation of clavulanic acid (Formulation #1) 
contains stearic acid and Avicel in the middle layer separating the two active ingredients. 
This layer helps prevent the passage of moisture into the core. Formulation #3 represents 
a combination of the ingredients of the three layers of Formulation #1 into a single layer 
tablet. It can be concluded that the compression-coated form with the stearic acid in the 
center layer separating the two active ingredients results in an increase in clavulanic acid 
stability. 
Photographs were taken for Formulation #1, #5, and the marketed formulation 
after 24 hours at 96% relative humidity (Figure 2.4) and after 1.83 days at 45% relative 
humidity (Figure 2.5). Formulations #5 and the marketed formulation  were highly 
discolored as a result of degradation of clavulanic acid. Formulation #1 showed no 
discoloration in the amoxicillin layer. This visual evidence is consistent with the data 
depicted in Figures 2.2 and 2.3, indicating that the new Formulation #1 is more stable to 
the presence of moisture than the marketed formulation. Figure 2.2. Clavulanic acid stability at 97% relative humidity. 
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Figure 2.4. Tablets containing amoxicillin and clavulanic acid exposed to 97%  relative 
humidity.  Orange color  is  associated with clavulanic  acid  degradation.  Right: 
Formulation #1; center: The marketed formulation; left: Formulation #3. 
Figure 2.5. Tablets containing amoxicillin  and clavulanic acid exposed to 45% relative 
humidity.  Orange color  is  associated with  clavulanic  acid  degradation.  Right: 
Formulation #1; center: The marketed formulation; left: Formulation #3. 20 
The core of Formulation #1 does discolor as degradation of clavulanic acid 
occurs, but the degradation is much slower than when clavulanic acid and amoxicillin are 
intimately mixed. 
Figures 2.6 and 2.7 show that amoxicillin  is somewhat more stable  in 
Formulations #1 and #2 than in the marketed formulation, and other tested formulations. 
It can be concluded that the separation of amoxicillin and clavulanic acid is useful to 
enhance the stability of both amoxicillin and clavulanic acid. 
Disintegration and dissolution 
Disintegration times for Formulation #1 and the marketed formulation were about 
19 minutes and 17 minutes respectively. As shown in Figures 2.8 and 2.9, about 100% of 
amoxicillin and clavulanic acid dissolved within 30 minutes for both Formulations #1 and 
the marketed formulation thus meeting the USP requirements which specify that not less 
than 85% of the labeled amount of amoxicillin and clavulanic acid is dissolved in 30 
minutes. 
The rate of dissolution of both amoxicillin and clavulanic acid is different for 
these two products. The rate of dissolution of amoxicillin from Formulation #1 is faster 
than from the marketed formulation, while clavulanic acid is released at a slower rate 
from Formulation #1 than from the marketed formulation, particularly during the first 12 
minutes of dissolution. This difference was expected due to the different formulation 
design of the two products. Figure 2.6. Amoxicillin stability at 97% relative humidity. 
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 Figure 2.8. Dissolution profile of amoxicillin. 
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The marketed formulation is a single layer tablet. Disintegration of the tablet 
gives an equal proportion of the total granules to be dissolved of both amoxicillin and 
clavulanic acid during all time intervals. The small difference in dissolution between 
clavulanic acid and amoxicillin in the marketed formulation can, therefore, be attributed 
to the difference of solubility and particle size. 
The center layer of Formulation #1 is not expected to affect the dissolution of 
amoxicillin because they are not intimately mixed. However, it may affect the dissolution 
profile of clavulanic acid because it must disintegrate before clavulanic acid starts to 
disintegrate. The outer layer of Formulation #1 was designed to disintegrate very rapidly 
to allow for disintegration of the center layer. Consequently, the dissolution rate of 
amoxicillin in Formulation #1 was faster than in the marketed formulation. 
Retardation of clavulanic acid dissolution during the first 12 minutes was due to 
the time required for the center layer and the outer layer to disintegrate. Once these two 
layers eroded, clavulanic acid dissolved rapidly which explains the slight difference of 
dissolution of clavulanic acid from these two products after the first 12 minutes. The 
difference in time required for amoxicillin to be completely dissolved between 
Formulation #1 and the marketed formulation is only 14 minutes, and clavulanic acid 
dissolution rate is quite similar to the marketed formulation after the first 12 minutes of 
dissolution. 
These slight differences may not significantly affect the absorption rate or extent 
of both active ingredients. This conclusion is particularly expected in the case of 
chewable tablets, which are to be chewed before swallowing. 26 
Formulation assessment 
Usually, powders of angle of repose less than 30° are described as having good 
flow properties, while an angle of repose larger than 40° indicates poor flow properties 
(6). The angle of repose of each of the mixtures used in Formulation #1 (Table 2.3) 
indicates reasonable flow properties. The three layers of the compression-coated tablets 
should have good friability in order to withstand handling in a production environment. 
As shown in Table 2.4, the core and the final tablet have friability values within 
acceptable range (less than 1% weight loss). All weights of the twenty tablets tested 
(Table 2.5) were within the 5% limit which meets USP requirements which specify that 
not more than 2 tablets outside the 5% limit is allowed. 
Table 2.3. Angle of repose of the mixtures used in Formulation #1. 
Mixture #  Angle of repose 
1  27 
2  34 
3  32 27 
Table 2.4. Thickness, hardness and friability of Formulation #1. 
Tablet part  Hardness  Friability  Thickness 
(kg)  (%)  (mm) 
Core  4.7  0.34  2.2 
core and first coat  *  *  2.3 
Final tablet  >15  0.15  5.1 
*The tablet press used to make this layer provided low pressure. 
Table 2.5. Weight (mg) of finished tablet of Formulation #1. 
1033.4 
1011.2 
1037.7 
993.25 
993.63 
1021.4 
989.5 
998.5 
1026.1 
1034.5 
969.87 
975.59 
996.94 
1027.5 
1007.5 
989.99 
1016.0 
980.57 
1003.2 
1002.6 28 
CONCLUSIONS 
Clavulanic acid is highly moisture sensitive substance, and  discolors intensely 
upon exposure to high humidity. Separation of clavulanic acid and amoxicillin can be 
achieved in the same dosage form as multiple compression-coated tablet; clavulanic acid 
in the core can be separated from amoxicillin in the outer coat by inactive ingredients in 
the middle layer. Stability of clavulanic acid can be  maximized by incorporation of 
stearic acid in the middle layer, which forms hydrophobic barrier and prevents moisture 
passage into the core. The separation of the two active ingredients results in enhancing 
the stability of amoxicillin. 29 
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CHAPTER 3 
MULTIPLE LAYER COMPRESSED-COATED FORMULATIONS
 
OF AMOXICILLIN/CLAVULANATE SWALLOW
 
TABLETS
 31 
ABSTRACT
 
A compressed-coated swallow tablet formulation of Amoxicillin/clavulanate was 
developed. The tablet consisted of three parts: core, middle layer (inner coat) and outer 
layer (outer coat). Amoxicillin in the outer layer was separated from clavulanic acid in 
the core by inactive ingredients in the inner coat. The outer coat tended not to bind very 
well to the middle layer and to cap off; the formulation has been optimized to solve this 
problem. Dissolution profiles of amoxicillin and clavulanic acid from the compressed-
coated tablet formulation were similar to those from the marketed single layer 
formulation. The compressed-coated formulation and the marketed formulation showed 
similar amoxicillin stability to moisture. However, clavulanic acidic was less stable in the 
compressed-coated tablet formulation than in the marketed formulation, when the two 
formulations were exposed to high and medium humidity conditions. 32 
INTRODUCTION
 
A compressed-coated tablet consists of a core on which one or two coats are 
compressed. Such formulation design can be used to separate active ingredients and to 
improve drug stability to moisture and light (1). 
Amoxicillin, is an aminopenicillin which differs structurally from ampicillin only 
in the addition of an hydroxyl group on the phenyl ring (2). Amoxicillin is usually 
bactericidal in action. Concurrent administration of clavulanic acid does not alter the 
mechanism of action of amoxicillin (2). However, because clavulanic acid has high 
affinity for and binds to certain 13-lactamase that generally inactivate amoxicillin, 
concurrent administration of the drug with amoxicillin results in a synergistic bactericidal 
effect and expands the spectrum of activity of amoxicillin against many strains of 13­
lactamase producing bacteria (2). Amoxicillin and clavulanic acid is commercially 
available for oral administration as film-coated tablets (2). Each tablet contains 250 or 
500 mg of amoxicillin and 125 mg of clavulanic acid. The tablet should be stored in tight 
containers at temperature less than 24 °C; exposure to excessive humidity should be 
avoided (2). 
The objective of this study is to develop a formulation of amoxicillin/clavulanate 
as a compressed-coated tablet with clavulanic acid in the core and amoxicillin in the outer 
coat. This formulation design can prevent mottling of the tablet that results from 
discoloration of clavulanic acid because of hydrolysis by moisture and oxidation by 
sunlight. 33 
MATERIALS AND METHODS 
Amoxicillin trihydrate (lot # 6453-X5), potassium clavulanate-Avicel mixture (lot 
# CkA-91), and Magnesium stearate (lot # TB4236), were obtained from Biocraft Lab., 
Fairfield, NJ. Ac -Di -Sol® (modified cellulose gum) (lot # T325) was from FMC, Newark, 
DE. Sodium stearyl fumurate (Pruv®) (lot # 21201X) was from Mendell, Patterson, NY. 
Acetyltributyl citrate (Citroflex®) (lot # N414040)  was from Morflex Chemical Co., 
Greensboro, North Carolina. Eudragit® E 30 D (lot # 12851232), Eudragit® NE 30 D (lot 
# 1260812084), Eudragit® RS 30 D (lot # 0440218012) and Eudragit® RL 30 D (lot # 
0440218012) were obtained from Riihm Pharma, Malden, MA. 
Tablet manufacture, stability studies and dissolution studies were performed 
according to reference (3). 
RESULTS AND DISCUSSION 
Tablet manufacture and formulation 
Previous generic formulation of amoxicillin/clavulanic  as a compressed-coated 
chewable tablet with stearic acid in the middle layer showed more stability for clavulanic 
acid and amoxicillin than the marketed single layer formulation (4).  However, the 
dissolution profiles of the two active ingredients of the generic were slightly different 
from that of the marketed formulation (4). In addition, bioavailability studies (5) showed 
that the generic was not bioequivelent to the marketed formulation for clavulanic acid; 
clavulanic acid Tmax was delayed and its COX was relatively low for the generic in 34 
comparison to the marketed formulation (5). These differences were attributed to stearic 
acid, a known inhibitor of gastric emptying, which may delay the absorption of 
clavulanic acid. Accordingly, stearic acid was removed from the formulation of 
Amoxicillin/clavulanate oral compressed-coated tablet and Formulation #1 of was 
prepared and is listed in Table 3.1. 
Table 3.1. Formulation #1 of compressed-coated amoxicillin/clavulanate swallow tablet. 
Tablet part  Ingredient  Amount per tablet (mg)  Compression force (lb) 
Core  Clavulanic acid  312.7  1000 
Ac-Di-sol®  5.0 
Avicel® pH112  50.0 
Mg-stearate  3.7 
Middle layer	  Avicel® pH112  250.0  2000 
Mg-stearate  2.5 
Outer layer	  Amoxicillin  573.9  6000 
trihydrate 
Avicel® pH112  60.0 
Mg-stearate  6.3 35 
A schematic representation of the tablet with the dimensions of each layer  is 
shown in Figure 3.1. Each layer showed acceptable friability and hardness. However, the 
outer layer did not bond very well to the middle layer, as gaps were seen visually in the 
edges of the final tablet. Scanning electron microscopy of cross sections of the  tablet 
provided further information about how the tablet bonds together. Figure 3.2 shows a 
triple layer compressed-tablet under high magnifications. Gaps can be seen separating the 
outer coat and the rest of the tablet and within the outer coat. 
Figure 3.1. Schematic representation of amoxicillin/clavulanic acid compression-
coated swallow tablet. 
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Figure 3.2. Cross section of compression-coated amoxicillin/clavulanic acid swallow 
Tablet. Magnification, A = X14 and B = X45. 37 
Capping of the outer coat in a compressed-coated tablet 
Here are several reasons for capping of the outerlayer in a compressed-coated 
tablet. The coat might not have a good cohesiveness or ability to adhere tightly to the 
core (1). The outer coat might not be plastic enough to expand slightly with the slight 
swelling of the core after the extrusion of the completed tablet from the die (1). The 
coating may cap off because there is an excess amount of fine powder, glidant, 
disintegrant or lubricant, since these have little cohesiveness (1). The cores may have 
been compressed too hard and their surfaces densified so that the coating can not bond. 
Hard cores tend to be elastic rather than plastic upon release of the pressure; when the 
core is ejected from the die, the rebound of the core pops the top off the tablet (1). 
Improper centration of the core either vertically or horizontally produces weak edges 
(Figure 3.3) (1), and the coat will not hold together. 
Figure 3.3. Examples of off-centering. Faults in compression coating: a) unequal coating; 
b) cocking; (c) and (d) off-center. 
( 
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Optimization of Formulation #1 to reduce the capping of the outer layer 
It is customary to use the same material in the coating as  in the core, a practice 
based on the theory that like substances will bond better to like than to different materials 
(1). In Formulation #1, the same diluent and lubricant were used in all layers of the 
compressed-coated tablet. Wolf (6) has recommended that addition  of 2% acacia can 
improve the binding of the coat to the core, and 1.75% of gelatin can impart elasticity for 
that coat. Acacia and gelatin are hygroscopic substances; they might interfere with the 
stability of amoxicillin and clavulanic acid, which are moisture sensitive substances (7,8). 
Thus, they were not investigated. 
Metallic stearates can interfere with the bonding of the layers of a compression-
coated tablet (1). For this reason, the effect of changing Mg-stearate in Formulation #1 
with other lubricants, such as Pruv®, Lubritab® and DL-leucine, on the cohesiveness of 
the compression-coated tablet was studied by visual inspection of compressed, and often 
cracked tablets. Among the three lubricants, it was found that the use of Pruv® results in 
fewer and narrower gaps in the edges of the final tablet. 
As a way of enhancing bonding between layers in conventional layer tablets, the 
first layers are compressed at very low compression force and the last layer is compressed 
into the soft layers at high compression force (1). In compression-coatedtablets, the cores 
are required to be sufficiently hard in order to withstand handling in the transfer devices, 
and transfer on the coating machine; the core should have good friability and, at the same 
time, should be soft enough for sufficient bonding with the coat (1).  The compression 
forces used for the core and middle layer in Formulation #1 were the minimum to achieve 
acceptable friability in the two layers. 39 
In order to achieve formulations for the core, inner coat and outer layer that have 
an acceptable layer friability at the lowest possible compression force, and have positive 
effect on the cohesiveness of the final tablet, ingredient changes in the three layers were 
studied and are listed in Table 3.2. According to Table 3.2, increasing the percentage of 
Avicel® in the outer layer, inclusion of Emcompress® (dicalcium phosphate) in the core 
and middle layer, and reducing the lubricant percentage in the outer layer contributes to 
enhancing the compressibility of the final tablet. In addition, reducing the percentage of 
lubricant in the core and middle layer improves both layer friability and compressibility 
of the final tablet. Formulation #1 was adjusted according to Table 3.2 and is listed as 
Formulation #2 in Table 3.3. Formulation #2 showed less cracking and had fewer gaps in 
the final tablet than Formulation #1. 
One approach which may reduce capping of the outer coat in Formulation #2 is to 
granulate Avicel® with a nonhygroscopic polymer, that can improve its cohesiveness, 
adherence to the core and elasticity, before it's addition to the mixture of the outer coat. 
Acrylic polymer, available under the trade name Eudragit ®, are used in coating tablets, 
capsules and granules for several purposes, such as improving drug shelf life, delaying 
drug absorption and improving appearance (9). In addition, some types of this class of 
polymers, such as Eudragit® E 30 D, Eudragit® NE 30 D, Eudragit® RS 30 D, and 
Eudragit® RL 30 D, are used as binders in powder granulation to improve compression 
characteristic on tableting (hardness and abrasion) (9). Eudragit® E 30 D and Eudragit® 
RL 30 D are rapidly disintegrating polymers (9). 40 
Table 3.2. Effect of ingredient changes on layer friability and cohesiveness of 
compressed-coated tablet of Formulation #1. 
Ingredient change  Effect on layer friability'  Effect on the cohesiveness of 
the final tablet2 
Increasing the percentage of  No effect  Positive 
Avicel® in the outer layer 
Replacement of Avicel® in  No effect  Positive 
the core with an equivalent 
amount of Emcompress® 
Replacement of Avicel® in  Negative  Positive 
the middle layer with an 
equivalent amount of 
Emcompress® 
Replacement of Avicel® in  No effect  Negative 
the outer layer with an 
equivalent amount of 
Emcompress® 
Replacement of Avicel® in  No effect  No effect 
the core with an equivalent 
amount of CaSO4.2H20 
Replacement of Avicel®  Negative  Negative 
pH112 in the middle layer 
with an equivalent amount of 
CaSO4.21120 
Replacement of Avicel® in  No effect  Negative 
the outer layer with an 
equivalent amount of 
CaSO4.2H20 
Replacement of Avicel® in  No effect  No effect 
the core with an equivalent 
amount of lactose anhydrous 
Replacement of Avicel® in  No effect  No effect 
the middle layer with an 
equivalent amount of lactose 
anhydrous 41 
Table 3.2 (Continued) 
Replacement of Avicel® in 
the outer layer with an equivalent 
amount of Lactose anhydrous 
Reducing the percentage of 
lubricant in the core 
Reducing the percentage of 
lubricant in the middle layer 
Reducing the percentage of 
lubricant in the outer layer 
No effect  Negative 
Positive  Positive 
Positive  Positive 
No effect  Positive 
1 Based on the compression force required to achieve the same or better layer friability
 
than in Formulation #1: lower force: positive; the same force: no effect; higher force:
 
negative.
 
2 Based on visual inspection of the final tablet.
 42 
Table 3.3. Formulation #2 of compressed-coated amoxicillin/clavulanate swallow tablet. 
Tablet part  Ingredient  Amount per  Compression  Friability 
tablet (mg)  force (lb) 
Core  Clavulanic acid  312.7  500  0.29 
Ac-Di-sol®  5.0 
Emcompress®  100.0 
Pruv®  2.1 
Middle  Avicel®  100  3000  0.54 
layer  Emcompress®  250.0 
Pruv®  0.9 
Outer layer  Amoxicillin  573.9  7000  0 
trihydrate 
Avicel® pH112  150.0 
Pruv®  3.6 43 
Eudragit
to NE 30 D, a permeable and swellable polymer, possesses a high binding 
capacity and elasticity and, therefore, has special opportunity for application in 
granulation (9). Eudragit® RS 30 D has low permeability that is independent of pH (9). 
These acrylic polymers were tested for their effect on the compressibility of the final 
tablet as a granulating agent for Avicel® in the outer layer. The effect of increasing 
plasticity of the Avicel® granules with Citroflex® on tablet compressibility was also 
studied. 
Table 3.4 Shows that granulation of Avicel® with any of those acrylic polymers, 
particularly Eudragit® NE 30 D, as well as increasing the plasticity of the granules can 
minimize the capping of the outer coat without significant effect on disintegration of the 
final compressed-coated tablet. Because drugs were not involved in this granulation, and 
disintegration of the final tablet was not prolonged, Avicel® granulation with any of these 
acrylic polymers in the outer layer will not affect the dissolution of amoxicillin or 
clavulanic acid. 
Based on the foregoing formulation tests, a final formulation of compressed-
coated amoxicillin/clavulanic acid swallow tablet was selected as listed in Table 3.5 as 
Formulation #3. Further stability and dissolution studies were performed on this 
formulation. 44 
Table 3.4. Effect of granulation* of Avicel® in the outer layer of Formulation #2 with 
several types of Eudragit® polymers with or without 5% Citroflex® on tablet 
disintegration and cohesiveness. 
Granulation process 
No granulation 
Granulation with Eudragit® E 30 D 
Granulation with Eudragit® NE 30 D 
Granulation with Eudragit® RS 30 D 
Granulation with Eudragit® RL 30 D 
Granulation with Eudragit® E 30 D 
plus 5% Citroflex® 
Granulation with Eudragit® NE 30 
plus 5% Citroflex® 
Granulation with Eudragit® RS 30 D 
plus 5% Citroflex® 
Granulation with Eudragit® RL 30 D 
plus 5% Citroflex® 
Disintegration 
Time 
(minutes) 
6 
6 
8 
11 
13 
5 
9 
9 
9 
Time after which crack in the 
outer layer was visually seen 
(days) 
Immediately 
2 
3 
1 
1 
4 
6 
4 
2 
*12 ml Eudragit® dispersion (30%) with or without 5% Citroflex® were used in 
granulating 10 gm Avicel ®. 45 
Table 3.5. Formulation #3 of compressed-coated amoxicillin/clavulanate swallow tablet. 
Tablet part	  Ingredient  Amount per tablet (mg) 
Core	  As in Table 3.3  As in Table 3.3 
Middle layer	  As in Table 3.3  As in Table 3.3 
Outer layer	  Amoxicillin trihydrate  573.9 
Avicel® pH112 Granulated  with  150.0 
Eudragit® NE 30 D and Citroflex® 
According to Table 3.5 
3.6 Pruv® 46 
Stability studies 
Figures 3.4 and 3.5 illustrate that both the marketed formulation and Formulation 
#3 show similar stability for amoxicillin at low humidity, however, amoxicillin was 
slightly more stable in Formulation #3 than in the marketed formulation, which might 
suggest that separation of clavulanic acid and amoxicillin helps in stabilization of 
amoxicillin. 
The marketed formulation shows more stability  for clavulanic acid than 
Formulation #3 (Figures 3.6 and 3.7). In a previous study, it was found that formulation 
of clavulanic acid as a compressed-coated chewable tablet with Avicel® in the middle 
layer had similar stability to that of the marketed single layer chewable tablet 
formulation. Unlike the chewable tablet, the marketed swallow tablet is coated with three 
coats: hydroxypropylmethyl cellulose, methylacrylic acid, methylacrylate copolymer and 
shellac (10). These three coats might provided a barrier to moisture and contribute to 
enhancing the stability of clavulanic acid in the marketed formulation. The degradation of 
clavulanic acid in the core of Formulation #3 might be enhanced by cracking in the outer 
coat upon exposure to moisture; the compressed-coated tablet tends to crack upon 
exposure to humidity, which will increase the amount of moisture that can reach into the 
core. It is expected that application of polymer coats over the multiple compression-
coated tablet will greatly enhance clavulanic acid stability in the core. Figure 3.4. Amoxicillin stability at 97% relative humidity. 
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Dissolution studies 
Figure 3.8 shows that amoxicillin dissolves relatively faster from Formulation #3 
than in the marketed formulation. This is due to the fact that the outer amoxicillin layer in 
the compressed-coated tablet disintegrates  faster than a single layer mixture of 
amoxicillin and clavulanic acid. 
Despite the difference in formulation design between the marketed formulation 
and Formulation #3, clavulanic acid in the two formulations showed similar dissolution 
profiles (Figure 3.9). 
The outer layer, which did not bond very firmly to the inner core, might cap at 
the beginning of dissolution because of exposure to water, consequently, clavulanic acid 
dissolution may have started before complete disintegration of the outer coats. 120 
Figure 3.8. Dissolution profiles of amoxicillin. 
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CONCLUSIONS 
Compression coated tablets can be used to separate active ingredients in the same 
in dosage forms. It consists of three layers, and each layer must have good friability and 
compressibility. Consequently, compression of the outer coat into the hard inner core is 
challenging. The dosage for has been applied to amoxicillin and clavulanic acid. The 
outer layer containing amoxicillin showed cracks after compression into the inner coat 
containing clavulanic acid. The problem was minimized by incorporation of inactive 
ingredients that can have good friability at low compression force in the core, such as 
Emcompresse.  Granulation of diluent in the outer layer with rapidly disintegrating 
acrylic polymers improved the bonding of the outer layer to the inner core. Cracking of 
the outer coat diminished its ability to form moisture barrier that will prevent the passage 
of moisture into the core, which lowered the stability of clavulanic acid. 55 
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CHAPTER 4 
BIOEQUIVELENCE OF AMOXICILLIN/CLAVULANATE
 
COMPRESSED-COATED TABLET FORMULATION.
 57 
ABSTRACT
 
The bioequivelence of a new compression coated formulation, containing 500 mg 
amoxicillin as amoxicillin trihydrate, and 125 mg clavulanic acid as potassium 
clavulanate was compared to Augmentin®. Urinary excretion rates of both drugs were 
monitored as a non-invasive means to compare bioavailability. A randomized two-way 
crossover bioequivelence study was designed to evaluate bioavailablities of both 
formulations in healthy human volunteers (5 men and 3 women) between the ages of 18 
and 41. An average 76.65% and 13.96% of the administered dose of amoxicillin and 
clavulanic acid, respectively, were excreted unchanged in the urine within 6 hours after 
oral administration. Bioequivelence of the two formulations was evaluated using the 
power approach and the two one-sided t-test. According to the power approach, the two 
formulations were equivalent for amoxicillin and clavulanic acid. The results of the two 
one-sided t-test showed that AUC and Cmax of amoxicillin for the tested formulation 
were within El 20% of those of the reference product. However, AUC and Cmax of 
clavulanate were not within p. 20%. Bioinequivelency of the two formulations for 
clavulanic acid might be due to small sample size and high intra-subject variation. 58 
INTRODUCTION 
Amoxicillin, D+)-a-amino -p-hydroxybenzyl-penicillin trihydrate, is an analog of 
ampicillin derived from the basic penicillin nucleus and has widespread therapeutic use. 
Clavulanic acid, Z-(3R, 5R)-2-((-hydroxyethylidene) clavam-3-carboxylate is a potent 
inhibitor of 13-lactamase enzymes, including those produced by 1-1.influenzae, S. aureus, 
N gonrrhoeae, and Bacteroides fragilis (1). Clavulanic acid has weak antibacterial 
activity itself (1). However, when combined with other 13-lactam antibiotics like 
amoxicillin, the combination is very active against many bacteria resistant to the 3- lactam 
alone. The usual adult oral dose of amoxicillin and clavulanate potassium is one 250 mg 
tablet containing 250 mg of amoxicillin and 125 mg of clavulanic acid every 8 hours (1). 
For more severe infections and infections of the respiratory tract, the usual adult oral 
dosage is one 500 mg tablet containing 500 mg of amoxicillin and 125 mg of clavulanic 
acid every eight hours (1). 
Amoxicillin trihydrate and potassium clavulanate are both relatively stable in the 
presence of acidic gastric secretions and well absorbed following oral administration (1). 
Peak serum concentrations of amoxicillin and clavulanic acid are generally attained 
within  1-2.5  hours following  oral  administration of amoxicillin and potassium 
clavulanate in fasting adults (1). Serum concentrations of amoxicillin and clavulanic acid 
both decline in a biphasic manner and half-lives of the drugs are similar (1). Following 
oral administration of amoxicillin and potassium clavulanate in adults with normal renal 
function, amoxicillin has an elimination half-life of 1-1.3 hours and clavulanic acid has 
an elimination half-life of 0.78-1.2 hours (1). Following a single dose of amoxicillin and 
potassium clavulanate in adults with normal renal function, approximately 50-73% and 59 
25-45% of amoxicillin and clavulanic acid, respectively, are excreted unchanged in the 
urine within 6-8 hours (1). Aomxicillin and clavulanic acid are both distributed into the 
lungs, pleural fluid, and peritoneal fluid. Low concentrations (i.e., less than 1 µg/ml) of 
each drug are attained in sputum and saliva (1). Only minimum concentrations of are 
attained in CSF following oral administration of aomxicillin and clavulanate potassium in 
patients with uninflamed meninges; higher concentrations may be attained when 
meninges are inflamed (1). 
Aluminum hydroxide, milk and cimetidine have some influences on the 
bioavailability of a single dose of oral Augmentin, but the effects are unlikely to be of 
therapeutic importance  (1).  Oral administration of probencid  shortly  before or 
concomitantly with amoxicillin and clavulanate potassium slows the rate of renal tubular 
secretions of amoxicillin and produces higher and prolong serum concentrations of 
amoxicillin (3,4,5). However, probencid does not affect serum concentration of 
calvulanic acid, which might be due to the minor role of tubular secretion of clavulanic 
acid  (5).  Calcium channel blockade significantly enhances both absorption and 
bioavailability of amoxicillin without modifuing its distribution or elimination (6); 
nifidipine can enhance intestinal amoxicillin intake by stimulating its active transport. 
The objective of this study is to compare the bioavailability of amoxicillin and 
clavulanic acid from a compression-coated tablet (Figure 3.1) to that from the marketed 
conventional single layer tablet (Augmenting). Each tablet of each formulation contains 
500 mg amoxicillin as amoxicillin trihydrate and 125 mg clavulanic acid as potassium 
clavulanate. Hereafter, the compressed-coated formulation will be referred as the new 
formulation. 60 
MATERIALS AND METHODS
 
Subjects 
The study was approved by the Oregon State University Institutional Review 
Board for the Protection of Human Subjects. All subjects (3 female and 5 male) were 
healthy volunteers, between the ages of 18 and 41 years old (mean 25), and weighing 
between 130 and 190 lbs (mean 163). All subjects were non-smokers, with no known 
allergic reaction to penicillin or any other antibiotics, and were not on any previous or 
current medication including. None of the subjects had history of gastrointestinal, kidney, 
or liver disease. 
Study design 
After overnight fasting the day of the study, the subjects had a standard breakfast 
which consisted of a plain bagel, one ounce of cream cheese and a 236 ml juice drink 
(Sunny delight'). Absorption of amoxicillin and clavulanic acid from Augmentin® is 
reported to be unaffected by food. Therefore, Augmentin® may be administered with 
meals which can minimize the possibility of GI tract disturbances. Either the compressed-
coated tablet formulation or Augmentin® was assigned as a starting dose and the tablet 
was given within 5 minutes after breakfast was taken. Subjects were instructed not to eat 
or drink tea or coffee for the next two hours with no subsequent restrictions. Urine was 
collected in labeled Whirl-Pak® bags at 1, 2, 3, 4, 5 and 6 hours after administration for 
HPLC analysis. After at least a 24 hour washout period, the alternate product was given 
to subjects. 61 
Liquid chromatography 
Aomxicillin and clavulanic acid were analyzed separately using two independent 
HPLC systems. A Waters solvent pump (Waters Associates, Inc., Milford, MA, U.S.A.) 
was used to pump degassed mobile phase through a C18 reverse-phase column (inner 
diameter 4.6 mm by 25 cm, particle size, 5 gm; Rainin Instrument Company, Inc., 
Woburn, MA) with a flow rate of 1.3 ml/min for amoxicillin and 2.0 ml/min for 
clavulanic acid. The eluent was monitored for amoxicillin at 229 nm using Waters model 
441 absorbance detector. In order to lengthen the retention time and obtain distinct peaks 
from interfering components in urine (7), clavulanic acid was assayed by reacting the 
sample with immidazol; the derivative was detected at 313 nm using Waters model 440 
absorbance  detector.  The  mobile  phase was 0.0005M potassium  dihydrogen 
orthophosphate in 5% methanol in deionized water for amoxicillin and 0.001M potassium 
dihydrogen orthophosphate in 6% methanol in deionized water (adjusted to pH 3.0 with 
phosphoric acid) for clavulanic acid. Injection volumes  were 20  1.1.1 and 50 gl for 
amoxcillin and clavulanic acid, respectively. Absorbance of amoxicillin and clavulanic 
acid was recorded individually through two channels of a Shimadzu CR501 Chromatopac 
(Shimadzu Corporation, Chromatographic & Spectrophotomeric Instruments Division, 
Kyoto, Japan). 62 
Sample preparation for HPLC analysis 
Once the urine sample was returned to the laboratory, the full volume was 
measured and 1 ml urine was immediately buffered to pH 6 to ensure stability. 
Sulfadiazine and paracetamol, at concentrations to achieve appropriate peak area ratio, 
were used as internal standards for amoxicillin and clavulanic acid, respectively. The 
imidazole reagent for clavulanic acid derivitization was prepared by dissolving 8.25 gm 
of imidazol in 24m1 deionized water plus 2 ml of 5M HCL. The solution was adjusted to 
pH 6.8 by addition of 5M HCL, and volume was made up to 40 ml with deionized water. 
Sample for clavulanic acid analysis was prepared by reacteing 100 µl solution containing 
clavulanic acid with 400 µl immidazol reagent for 10 minutes, followed by the addition 
of 50 µl sulfadiazine. Samples for amoxicillin analysis were mixed with equal volumes of 
paracetamol before HPLC analysis. 
Data analysis 
WIN-NONLIN® was used to calculate bioavailability parameters (Cmax, Tmax 
and AUC04). Cmax is defined as the maximum urinary excretion rate of drug and Tmax 
is the time corresponding to the maximum urinary excretion rate of drug. AUC is defined 
as the area under the curve depicting excretion rate plotted with respect to midpoint of 
time interval. Cmax and Tmax were directly taken from the data. AUC was estimated by 
the trapezoidal rule. AUC and Cmax were statistically analyzed by ANOVA using SAS® 
and Tmax was analyzed by the non-parametric statistical test Wilcoxon rank-sum test 
using S-Plus®. 63 
RESULTS AND DISCUSSION 
Figures 4.1 and 4.2 show that the mean excretion rates for the two formulations 
for amoxicillin and clavulanic acid are similar. The pharmacokinetic parameters of both 
drugs in each formulation are shown in Tables 4.1 and 4.2. Previous bioequivelence study 
of two compression-coated chewable tablet formulations and the marketed chewable 
tablet (each contained 250 mg amoxicillin and 62.5 mg clavulanic acid) (8) showed that 
the average Cmax and AUC in the three formulations were 62.19 and 174.14, 
respectively, for amoxicillin and 4.33 and 9.96, respectively, for clavulanic acid. 
Compared to these results, The average values of AUC and Cmax in Tables 4.1 and 4.2 
are approximately doubled for the doubled dose (500 mg), which would suggest that both 
amoxicillin and clavulanic acid follow linear pharmacokinetics. 
Compared to 76.87% and 14.61% for the marketed formulation, it was calculate 
that 76.43% and 13.30% of amoxicillin and clavulanic acid, respectively, were excreted 
unchanged within 6 hours of administration of the compression-coated tablet formulation. 
Power approach and two one-sided test procedures (9,10) were used to assist in 
evaluating bioequivlence of the two formulations. 
In the power approach, a decision on the bioequivlence of two formulations is 
based solely upon a test of the null hypothesis (Ho): 
Ho:  - pa = 0 
Against the alternative hypothesis (Hi): 
H1: 'kr - 1.1R # 0 
where p.T is the population mean for the test formulation and p.R is the population mean 
for the reference formulation. Figure 4.1. Mean urinary excretion rates of amoxicillin. 
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Table 4.1. Amoxicillin pharmacokinetic parameters. 
Subject  Formulation 
Augmentin® New  Augmentin® New  Augmentin® New 
Cmax  Tmax  AUCo-t 
1  170.85  191.76  1.50  1.5  430.92  445.99 
2  161.36  126.35  2.50  1.5  371.15  379.87 
3  130.66  141.22  1.50  3.59  292.87  578.90 
4  54.00  66.24  1.50  3.42  135.48  199.22 
5  116.59  179.38  1.45  0.44  347.46  272.81 
6  131.40  57.27  1.50  4.72  189.46  104.48 
7  296.02  135.98  4.50  2.5  727.70  505.88 
8  157.59  110.87  2.50  2.5  418.23  332.12 
Average  152.31  126.13  2.12  2.52  364.16  352.41 
SD  68.61  47.85  1.07  1.37  180.38  158.59 
CV  45.05  37.94  50.27  54.47  49.53  45.00
 67 
Table 4.2. Clavulanic acid pharmacokinetic parameters. 
Subject  Formulation 
Augmentin® New  Augmentin® New  Augmentin® New 
Cmax  Tmax  AUCo-t 
1  14.90  9.56  1.50  1.50  28.10  25.56 
2  5.05  5.91  2.50  1.50  13.36  11.30 
3  6.29  6.29  2.50  3.60  16.89  16.14 
4  1.75  4.05  1.50  1.50  3.43  7.23 
5  6.93  5.32  1.45  0.44  19.34  10.27 
6  15.60  1.12  1.5  2.80  28.98  4.23 
7  8.40  12.03  1.5  1.50  14.82  26.50 
8  9.66  9.43  1.5  1.50  16.19  23.67 
Average  8.57  6.71  1.74  1.79  17.64  15.61 
SD  1.68  3.48  0.47  0.97  8.21  8.70 
CV  55.33  51.87  26.79  53.92  46.54  55.72 68 
Analysis of variance (ANOVA) is the standard method of choice for evaluating a 
bioequivelence study using the power approach. Using an F-ratio, the null hypothesis of 
no difference between the formulations is tested at  the 5% level of significance. 
Differences between subjects and between periods can be tested at the same time. 
Significant differences between subjects will almost always be present and reflects 
biological variation between individuals. Significant differences between periods are not 
expected to be found. 
For the parameter of Tmax, the use of ANOVA is not appropriate. The values 
obtained for this parameter come from a discrete data set (i.e. the preselected sampling 
times) and can be poor estimates of the true value.  It  is recommended that a 
nonparametric method, such as Willcoxon statistic, be used to test for differences in 
Tmax between the formulations. 
The two one-sided tests procedure involves testing two interval hypotheses 
Hol: 'IT  µR <01  (right tail) 
H11: IAT 
and 
1102. µT µR >02  (left tail) 
H12: PT  -4)2 
The two one-sided tests procedure consists of rejecting the interval hypothesis Ho 
and thus concluding equivalence of p.T and pa, if, and only if, both Hot and H02 are 69 
rejected at a chosen nominal level of significance. The logic behind this is that if one may 
conclude that Oi<IAT - RR, and also conclude that EiT - pa<02, then it has in effect been 
concluded that 01<µr - tiR<O2. Under the normality assumption that has been made, the 
two sets of one-sided hypotheses will be tested with an ordinary one-sided t-test. For a 
balanced study, it will be concluded that RI- and RR are equivalent if 
(XT 
= 
XR)  01  02 t2= 
(XT  XR) 
111  1 
1  ±  1 
nT  nR  nT  nR 
where S is the square root of the "error" mean square from the crossover design analysis 
of variance. ti_a(v) is the point that isolates probability a in the upper tail of the 
Student's t distribution with v degrees of freedom, where v is the number of degrees of 
freedom associated with the "error" mean square. 
Both the power approach and two one-sided tests are based on the assumptions of 
normal distribution and constant variance (10). A logarithmic transformation has the 
effect of bringing the distribution of data closer to a normal distribution and stabilizing 
the variance. It is often instructive to analyze the data twice, once with, and once without, 
a logarithmic transformation. In the large majority of cases, transforming the data has 
little or no influence on the final statistical outcome. It is now recommended that Cmax 
and AUC data should be logarithmically transformed prior to statistical analysis (10). In 
these cases the acceptance region for bioequivelence should range from 80% to 125%. 
Table 4.3 shows that according to the power approach the two formulations are 
equivalent for Cmax and AUC for both amoxicillin and clavulanic acid. Also, the two 70 
formulations are equivalent for Tmax according to Willcoxon sum-rank test. Based on 
two one-sided t-test (Table 4.4), the Cmax and AUC of the tested formulation are within 
p. 20% of those of the reference product for amoxicillin but not for clavulanic acid. 
Table 4.3. P-values for differences between formulations obtained by ANOVA for Ln-
Cmax and Ln-AUC04 and by Wilcoxon rank-sum test for Tmax. 
Amoxicillin  Clavulanic 
acid 
Parameter  Ln-AUC04  Ln-Cmax  Ln-Tmax  Ln-AUCot Ln-Cmax  Ln-
Tmax 
p-Value  0.80  0.33  0.42  0.64  0.52  0.90 
Table 4.4. t-Statistics calculated according to two one-sided t-test. 
Parameter  Augmentin® New  MSE  t2 
formulation 
Amoxicillin  Ln-AUCot  5.786  5.748  0.086  17.22  -24.29 
Ln-Cmax  4.934  4.762  0.106  3.86  -29.82 
Clavulanic acid Ln-AUC04  2.725  2.58  0.358  1.75  -8.23 
Ln-Cmax  1.975  1.724  0.54  -0.41  -7.02 
*Mean square error obtained from ANOVA table. 71 
The bioinequivelency of the two formulations for clavulanic acid might be due to 
the high intra-individual variability and small sample size. When the variation is large 
because of the inherent biological variability in the absorption and/or disposition of the 
drug (or due to the nature of the formulation), large sample sizes may be needed to meet 
the confidence interval criterion (11). Also, when the intra-subject variability is high the 
two one-sided t-test may not be appropriate, and indeed widened acceptance limits (70­
143%) may be recommended for bioequivelence testing (12). 
To calculate the optimum sample size needed to detect bioequivelency of the 
formulations, for both drugs (for AUC and Cmax), the following power calculation was 
used (11) 
N = (o'I A)* + Z  + 0.5(Za2)  Eq. [1], 
where N = sample size, a = level of significance (5%), 13 = 1-Power (0.2), a = standard 
deviation of the ratios of test:reference pharmacokinetic parameters, A = a "practically 
significant" difference (0.2). Z values are obtained from statistical tables. 
According to Table 4.5, AUC and Cmax of clavulanic acid are the most variable, 
consequently, the optimum sample size to test for bioequivelence of the two formulations 
is 85 which is about 10 fold of the sample size that was used in this study. However, 
AUC for clavulanic acid for the new formulation was 88% of clavulanic acid AUC for 
the reference, and Cmax was 78%. It seems clear that AUC is bioequivelent between the 
two formulations without conducting a study in 85 people. Cmax, however, can not be 
considered bioequivelent at this time. 72 
Table 4.5. Optimum sample size calculated according to Eq. 1. 
Amoxicillin 
AUC04 
Cmax 
a 
0.42 
0.39 
37 
32 
Clavulanic acid 
AUCo-t 
Cmax 
0.65 
0.65 
85 
85 73 
CONCLUSIONS 
Amoxicillin and clavulanic acid are excreted in measurable amounts in urine, 
which makes urine excretion data useful in measuring their pharmacokinetic parameters. 
A new compression coated tablet formulation  of amoxicillin and clavulanic was 
evaluated for bioequivelency to the marketed  conventional  single  layer  tablet 
formulation. Both formulations were bioequivelent for  amoxicillin for all the required 
pharmacokinetic parameters. However the two formulation were not bioequivalent for 
clavulanic acid for AUC and C-max. Sampling size  calculations, based on the 
pharmacokinetic parameters of the two active ingredients, showed that the number of 
subjects required to reveal any inequivelency between the two formulations is about three 
times the number of subjects participated in the study. 74 
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CHAPTER 5
 
CHARACTERISTICS OF NISIN 76 
STRUCTURE 
Nisin consists of 34 amino acid residues. The molecule possesses amino and 
carboxyl end groups, and five thioether bands form internal rings (1) (Figure 5.1). 
Although molecular mass of the nisin monomer is about 3500 (2), nisin usually occurs as 
stable dimers of a molecular mass of 7000 or tetramers of a molecular mass of 14000 (3, 
4). 
PHYSICAL AND CHEMICAL PROPERTIES 
As far as the amino acid is concerned, nisin possesses an amphiphilic character, 
with a cluster of bulky hydrophobic residues at the N-terminus and hydrophilic ones at 
the C-terminus (5). The distribution of polar and apolar residues over the molecular 
surface of nisin may be of relevance with respect to its mode of action and biological 
activity. Furthermore, nisin behaves as a cationic polypeptide with a positive charge of 3 
and hence an isoelectric point in the alkaline range. Nisin contains no aromatic amino 
acids, so it does not absorb UV-light at 260 or 280 tun (6). 
The solubility of nisin is highly dependent on the pH of the solution. It drops 
sharply and continuously as the pH is increased. In neutral and alkaline conditions, nisin 
is almost insoluble (7-10). The solubility ranges from 57 mg/ml at pH of 2.0 to about 1.5 
mg/ml at pH of 6.0; it drops further to 0.25 mg/ml at pH of 8.5, and then it levels off (9). 
In addition, nisin solubility is inversely related to buffer concentration (9). In non 
aqueous solvents, nisin is almost completely insoluble (11) Figure 5.1. Structure of nisin. Abu: 2-aminobutyric acid; Dha: dehydroalanine; Dhb: dehydrobutyrine. 
NH2 
COOH 78 
The stability of nisin is also pH dependent, with maximum stability occurring at 
near pH 2 (9) and significant inactivation occurring at alkaline pHs greater than pH 7 
(10,12). Indeed, nisin solution can be boiled in dilute hydrochloric acid at pH 2.5 or less 
without any loss of activity. Moreover, nisin remains stable after autoclaving at  115.6 °C 
at pH 2.0 but losses 40% of its activity at pH 5.0 and more than 90% at pH 6.8 (13). The 
stability of nisin solution to heating and storage depends not only on pH, but also on 
several other factors such as the chemical composition of the solution, the protective 
effect of proteins, the temperature, etc. For instance, nisin can be irreversibly adsorbed by 
some proteins. This adsorption probably accounts for the protective effect when nisin 
solutions are exposed to heat (8). 
BIOLOGICAL PROPERTIES 
Inhibition spectrum 
Nisin displays activity against Gram-positive bacteria, and has proven effective 
against a variety of spoilage bacteria in foods (11,14). Although normally not  active 
against Gram-negative bacteria and fungi, nisin can be an effective inhibitor of certain 
Gram-negative bacteria when used in combination with other compounds  such as 
chelating agents (15,16). In high concentrations, nisin has also shown activity against 
yeast (17). Of special interest, however, is nisin activity against several hazardous food 
pathogens, including Listeria monocytogenes (18,19), and sporeformers  such as 
Clostridium boutilinum types A, B, and E (20). 79 
Mechanism of nisin activity 
The exact mechanism of nisin antimicrobial activity is not completely understood, 
but it is generally believed that nisin acts on the bacterial cytoblasmic membrane, leading 
to pore formation, loss of cellular integrity, and subsequent cell death (14,21,22). The 
first step in the antibacterial process involves adsorption of nisin to susceptible bacteria 
(8). Normally nisin does not adsorb to Gram-negative bacteria, likely due to the barrier 
function of the lipopolysaccharide membrane characteristics of most Gram-negative 
species (23,24). However, following sub-lethal injury, many Gram-negative bacteria 
became sensitive to nisin (16). This was also observed for nisin producer strains such as 
lactococous lactis ATCC 11454 and Lc lactis 345/07, which are normally resistant to 
becteriocin but became sensitive following freezing (25). Once adsorption has taken 
place, a change in nisin conformation is believed to occur, and the hydrophobic moieties 
of the peptide are drawn into the hydrophobic bacterial membrane (26). Binding should 
also lead to increasing concentrations of the peptides at the membrane as compared to the 
concentration in solution (24), which in turn increases the probability of oligomerization 
and formation of peptide preaggregates (24). Due to the amphiphilic nature of nisin, 
charges are exposed on one side of the molecule which makes it rather unlikely that a 
peptide monomer could adopt a transmembrane orientation; moreover, a monomer should 
not be able to form a channel of the size determined in planar membrane experiments 
(24). Thus, oligomerization seems to be essential and should occur at the membrane 
surface (24). Increasing the energy of the membrane should then force the peptide 
oilgomer into a conducting state, presumably by adopting a transmembrane orientation in 80 
such a way that the hydrophobic face of the aggregate is exposed to surrounding lipids 
while the hydrophilic face forms the inner lumen of the pore (24). 
THE USE OF NISIN 
Toxicity of nisin 
The fact that nisin is produced by Lactococci which occur naturally in raw milk 
and cheese is an indication of its harmless nature: it has been ingested by humans and 
animals over past centuries, without apparent ill effect. While this does not rule out the 
possibility that nisin might have some adverse effects, it does indicate, at least, that nisin 
has low toxicity (27). The LD50 value of nisin was found to be similar to that of common 
salts, i.e. about 7g/kg body weight (28). Furthermore, consumption of nisin containing 
products would not result in alteration of the intestinal bacterial flora,  because nisin is 
inactivated by the enzymes of the intestinal tract (29,30). Moreover, nisin has no action 
on Gram-negative bacteria, which form substantial part of the intestinal flora (31). In 
addition, nisin cannot be detected in the saliva of humans 10 min after consumption of 
chocolate milk containing 200 IU/ml nisin and hence would not be expected to alter the 
nature of bacterial flora in the oral cavity (32). Furthermore, there is no evidence of 
sensitization to nisin in human beings (31). 81 
Applications 
Nisin is mainly used in the production of food to prevent spoilage by Gram-
positive bacteria, especially Clostridium, Staphylococcus, Bacillus and Listeria (12). In 
1989, nisin had been approved for use in many countries, under different restrictions (1). 
In 1988, the food and drug administration has affirmed the "generally recognized as safe" 
(GRAS) status given to nisin used in the production of certain pasteurized processed 
spread cheese (33,34). The addition of nisin to meat allows for a reduction of the nitrite 
content in the food (10). Nisin has been  shown to delay the production of toxin by 
Clostridium botulinum in fresh fish (35). In the production of beer, the addition of nisin 
may help in preventing spoilage due to lactic acid bacteria (36-38). The addition of nisin 
to canned vegetables and fruits has been demonstrated to allow milder heat treatment 
(39). In cosmetics, nisin is used to increase the shelf life of certain products, e. g., 
cosmetic ointments (12). 
PROTEIN-STABILIZED EMULSIONS 
Proteins are by far the most important class of emulsifiers  of oil-in-water 
emulsions in foods. They are amphiphilic molecules, and tend to bind to hydrophobic 
interfaces via hydrophobic parts of their structures. Stabilization of oil droplets in water is 
achieved by protein adsorption to the droplet surface as it can impart an electronic charge 
to droplet surfaces (40,41), result  in steric stabilization (42), or both. Approaching 
particles would experience an energy barrier higher  than thermal energy and so not 
approach closely enough to interact (43). 82 
Practical measurements of emulsifying activity of proteins generally results from 
combination of several factors, and it is often difficult to relate the molecular adsorption 
to the overall emulsifying properties because the structure, charge, composition and 
strength of the interfacial layer are all important. The amounts of individual proteins 
which adsorb to an oil-water interface do not seem to differ widely, and there is at present 
no single property of a protein which will allow prediction of how it will adsorb in the 
presence of other surface-active components. The functionality of an emulsion droplet is 
determined partly by the conformation which is adopted by the adsorbed protein, and this 
in turn depends on the primary, secondary and tertiary structures, the strengths of the 
bonds which maintain the secondary structure, and the conformational flexibility of the 
protein, the spatial arrangement of hydrophobic areas on the surface of the molecule, and 
the potential for intermolecular bond formation between adsorbed molecules. 
In general, emulsions are stable if the oil-water interface is surrounded with thick 
adsorbed layer of protein or other molecules which resists breakdown and thinning, so 
that the oil droplets are prevented from coalescing. To achieve this, the adsorbed 
molecules must lower the interfacial tension by as large an amount as possible, and this is 
most readily achieved when they possess considerable hydrophobic character. The ability 
of a protein to cover an interface is critical during the early stages of emulsion formation. 
All proteins make a layer of some thickness on the oil-water interface, and therefore may 
present a more rigid interfacial layer than do small molecule emulsifiers. In terms of 
stability, the proteins may be more effective, but in terms of overall effectiveness, it is 
often the smaller molecules which play an important part. The interplay between these 
two types of emulsifiers forms a new and important area for research. 83 
NISIN AT INTERFACES 
Nisin is a highly surface active molecule whose  adsorptive properties were 
recognized as early as 1949 when it was noted that nisin in culture remained with 
Lactococcus lactis cells rather than in the culture broth at pH 6 (44). In 1951, Friedman 
and Epstein (45) recognized that nisin could adsorb onto glass test tubes, and that 2 U/ml 
could be released when sterile, fresh broth was added to the empty tubes. They also found 
that even boiling with detergents and oxidizing agents was not capable of removing all 
the adsorbed nisin. Nisin adsorption at silanized silica and the retention of its antibacterial 
activity after adsorption was studied. It was found that nisin can adsorb to solid surfaces 
in a manner stable to rinsing, maintain activity and kills bacteria cells that have adhered 
(46-48). A patent on preparation of antibacterial surfaces with adsorbed bacteriocin was 
recently issued (49). It was shown that the adsorption of nisin air-water interface results 
in considerable reduction in surface tension (50). The adsorption of nisin at bacterial cell 
is pH dependent (51), with maximum adsorption at pH 6.5, and less than half adsorbed at 
pH 4.4 (11). Nisin has been considered to produce the same outcome as cationic, surface-
active detergent effect on the bacterial cell membrane because leakage of UV absorbing 
material from treated bacterial cells was observed (52). The adsorption of nisin to glass, 
bacterial  cells, and the air-water interface does not, however, suggest  the same 
mechanism of action as an emulsifying agent. Quite the opposite is expected. Nisin's 
adsorption at surfaces may be related to its' low water  solubility. Nisin is also almost 
completely insoluble in nonaqueuos solvents. Emulsifying surfactants must be attracted 
to both water and oil and orient into micelles with either water entrapped in oil or oil 
entrapped in water as a result of the emulsifier solubility in either water or oil. Thus, 84 
although nisin has adsorptive properties at cell and glass surfaces, it should not solubilize 
in oil-in-water mixture and not dissolve cell membrane by dissolving their structure into 
oil-in-water micelles. In fact,  it  is known that nisin does not work through such 
emulsifying action but rather works by adsorbing to bacterial cell walls and forming 
pores and channels through biological membranes. 
Caseins are probably the most widely used of the food proteins which have 
known emulsifying activity. They possess a relatively small amount of regularly tertiary 
structure and are conformationaly mobile. They possess extensive hydrophobic regions 
which are likely to act as points of attachment to the surface. In terms of native structure, 
they are fairly unique among proteins, and it  is evident that their structures, when 
adsorbed are not typical of all proteins. Because casein (particularly (3-casein) can spread 
rapidly it has high emulsifying power, so that relatively small amounts of casein can form 
stable emulsions. Other proteins are less flexible in their ability to rapidly cover an 
interface, and so casein is able to make emulsions with smaller droplet sizes than other 
proteins. Nisin is flexible and amphiphilic like casein, but lacks the aqueous solubility of 
casein. 85 
CONCLUSIONS
 
Nisin is a cationic polypeptide that showes antibacterial activity against wide 
range of Gram-positive bacteria. It found wide application as preservative in food 
products, such as milk and canned food. It is also used as preservative in cosmetic 
ointments. Due to its amphiphilic properties, surface activity, flexibility, intermediate 
size between proteins that are used in food emulsions and small emulsifiers used in 
pharmaceutical emulsions, stability to heat and pressure extremes, very low toxcicity and 
antibacterial activity, nisin might be a good alternative to emulsifiers currently used by 
the industry. 86 
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CHAPTER 6 
EFFICACY OF THE ANTIMICROBIAL PEPTIDE NISIN IN
 
EMULSIFYING OIL IN WATER
 90 
ABSTRACT 
Nisin is a small (3510 Da) cationic amphiphilic peptide that kills susceptible 
bacteria by insertion into membranes resulting in pore formation, and has found 
application as a "food grade" preservative in the food and beverage industries. The oil-in­
water emulsifying activity of nisin is characterized here in using emulsion conductivity 
measurements. Evaluation of nisin as an emulsifier was accomplished by measuring its 
ability to stabilize dispersed oil droplets in water. Emulsions were formed after 
homogenization of a volume of nisin solution and corn oil; the electrical conductivity was 
measured continuously. Qualitatively, the higher the emulsifying activity of a given 
emulsifier,  the  lower the  expected  conductivity  during  homogenization.  After 
homogenization, emulsion conductivity generally increases, reflecting that the dispersed 
oil droplets rise and coalesce to form a floating layer, and the rate of this increase 
provided a measure of emulsion stability. Nisin solutions at concentrations of 0.1, 0.5, 1, 
5, and 10 mg/ml were used to prepare emulsions. Nisin showed significant emulsifying 
activity in comparison to Tween® 80 and 13-casein. Nisin's emulsifying activity was also 
found to be highly concentration and pH dependent. 91 
INTRODUCTION 
Emulsions are one of the major types of food structures, ranging from relatively 
simple liquids, such as milk and milk products to the structures found in comminuted 
meat products or ice creams (1). Many drugs are administered as emulsions in order to 
increase chemical stability, improve bioavailability over solid dosage forms, allow a 
liquid dosage form for poorly soluble drugs, or achieve drug targeting (2, 3). Proteins 
used effectively in food emulsions include the milk proteins (caseins, a-lactalbumin and 
ii-lactoglobulin), egg proteins (from both egg white and yolk) and animal proteins, such 
as gelatin (1). Small emulsifiers used in pharmaceutical emulsions, such as Tween® 80, 
can cause systemic toxicity (4). For example,  lipid microemulsions, used to improve 
dissolution and oral bioavailability of hydrophobic drugs, are thermodynamically stable, 
which requires the addition of a high percentage of emulsifiers. Consequently, they can 
have serious  adverse  effects,  such  as  irritation of the  intestinal  mucosa and 
gastrointestinal bleeding upon oral administration, and hemolysis of red blood cells upon 
intravenous administration (4). 
Nisin is a highly surface active molecule whose adsorptive properties were 
recognized as early as 1949 when it was noted that nisin in culture remained with 
Lactococcus lactis cells rather than in the culture broth at pH 6 (5). In 1951, Friedman 
and Epstein (6) recognized that nisin could adsorb onto glass test tubes, and that 2 U/ml 
could be released when sterile, fresh broth was added to the empty tubes. They also found 
that boiling in the presence of detergents and oxidizing agents was not sufficient to 
remove all the adsorbed nisin. Nisin adsorption at silanized silica and the retention of its 
antibacterial activity after adsorption was recently studied (7-9). It was observed that 92 
nisin can adsorb to solid surfaces in a manner stable to rinsing, maintain activity and kill 
bacterial cells that have subsequently adhered. Nisin has an effect similar to cationic 
detergent effect on the bacterial cell membrane as leakage of UV absorbing material from 
treated bacterial cells was observed (11). Nisin can withstand activity loss during thermal 
processing and exposure to acidic environments and pressure extremes (12). These 
characteristics and others, such as non-toxicity, and antimicrobial activity (13) make it an 
attractive candidate for use as an emulsifier in food and pharmaceutical emulsions. 
The main objective of this work was to determine if there is any oil-in-water 
emulsifying activity and emulsion stabilizing capacity of nisin, and compare the results 
with those of Tweene 80 (a commonly used nonionic emulsifier in food and 
pharmaceutical emulsions) 
and 13-casein (an efficient food emulsion stabilizer). 
MATERIALS 
Pure nisin (about 5.0 x 107 IU/g) was obtained from Aplin and Barrett Ltd. 
(Dorset, U.K.). Tween® 80 (Lot No. 44H01211) and 13-casein (Lot No. 25H9550) were 
purchased from Sigma Chemical Co. (St Louis, MO). Monobasic sodium phosphate 
monohydrate (Lot No. 77892KLJP), dibasic sodium phosphate heptahydrate (Lot No. 
7914KJKA) and citric acid monohydrate (Lot No. 062777KMBX) were obtained from 
Mallinckrodt Specialty Chemical Co. (Paris, Kentucky). Sodium citrate (Lot No. 402346) 
was from J.T.T. Baker (Philipsburg, NJ). Corn oil (100% pure) was purchased locally 
(Hunt-Wesson, Inc. (Fullerton, CA)). 93 
METHODS 
Solution preparation 
Nisin was dissolved in 0.01 M sodium phosphate monobasic (pH 4.5), to assure 
complete solubilization. Sodium phosphate dibasic (0.01 M, pH 9.1) was then added to 
the nisin solution to bring the pH to 7.4. Nisin solutions of pH 5.2 and 3.0 were prepared 
using citrate buffer (0.01 M). The same buffers were used to prepare B-casein and 
Tween® 80 solutions. 
Emulsion conductivity measurement 
An apparatus for measuring emulsion conductivity was used, consisting of a glass 
column connected to a conductivity cell (Cat. No. 018014, Orion Research Inc., Boston, 
MA). A schematic of the apparatus is shown in Figure 6.1. The design was adapted from 
Kato et al. (14) and described by Suttiprasit et al. (6). A small lab homogenizer (Biospec 
Products, Bartlesville, OK) was used to homogenize  6.7 ml of corn oil and 20 ml of 
emulsifier solution; the duration of homogenization was 1.5 min. All experiments were 
performed at room temperature  (23-25°C). The electrical conductivity was recorded 
during homogenization and for 3.5 minutes after  homogenization. The conductivity 
curves generally consisted ofthree regions (Figure 6.2): region a-b which is an immediate 
consequence of the homogenization and emulsification process; region b-c during which 
the conductivity is maintained low and quite constant as a result of formation of a stable 
oil-in-water emulsion; and an ascending linear region (c-d) due to emulsion instability. --
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Figure 6.1. Apparatus for measurement of emulsion conductivity 
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Figure 6.2. Emulsion conductivity curve divided into three distinct regions. 
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Determination of emulsion activity and emulsion stability 
Both emulsion activity and emulsion stability were determined according to Kato 
et al. (14). The sharp initial drop in conductivity after homogenization is a result of 
mixing the nonconducting oil into the aqueous phase. This decrease depends on both the 
emulsion activity of a surfactant and its concentration: as a higher volume of oil is being 
dispersed, a lower conductivity  is expected during homogenization. Accordingly, 
emulsion activity (EA) can be defined as the difference between the conductivity in the 
aqueous phase immediately before homogenization (Cp) and the lowest conductivity 
obtained during homogenization (Co) (14): 
EA = Cp - Co  [1] 
Since the conductivity after homogenization would increase in proportion to the 
instability of the emulsion, the emulsion stability (ES) can be calculated using the linear 
portion of the conductivity curve after emulsification (14), or 
ES = (Cp-Co) X At/AC  [2] 
where At/AC is the reciprocal of the slope of the linear portion of the conductivity curve 
after homogenization. Kato et al. (14) suggested that the nonlinear portion of the curve 
during the first 15 s after homogenization was due to the rise of foam formed during 
emulsification. Accordingly, this part was not included in calculating emulsion stability. 97 
Image and particle size analysis 
All samples for image and particle size analysis were taken from the bottom of the 
glass colunm at about 3.5 minutes after homogenization. Samples for analyzing the shape 
of flocculated and coalesced particles were drawn from the upper, separated layer of the 
emulsion. An incident light microscopy image analysis system (IAS) was used to record 
images of suspended oil droplets. The IAS is composed  of a 486 IBM compatible 
computer interfaced to a Sony monitor and a Reichert Epistar incident light microscope 
to which a video camera (Cohu Inc., San Diego, CA) is attached. Image-Pro Version 2.0 
(Media Cybernetics®,  Silver Spring, MD) was used for digitizing images, and 
Visionplus-AT (Imaging Technology Inc., Bedford, MA) was used forimage processing. 
Images were recorded under 40X objective. The average diameter of oil droplets in 10 
images was taken as a measurement of particle size. 
RESULTS AND DISCUSSION 
Emulsion activity 
Figure 6.3 shows that conductivity becomes time independent at about one minute 
after the onset of homogenization. The decrease in conductivity  depends on the 
volume/area ratio of the dispersed phase. 
At constant homogenization energy input, the amount of dispersed oil droplets 
and their particle size depend on emulsifier interfacial activity. 98 
Figure 6.3. Emulsion conductivity curves for a) nisin b) 13-casein and c)  Tween® 80. 
Concentrations used from left for each emulsifier, 10.0, 5.0, 1.0, 0.5, and 0.1 mg/ml. The 
conductivity of each solution immediately before homogenization is indicated with an 
arrow on each curve. 
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The higher volume/area ratio of the dispersed phase during emulsification, the 
more emulsifier molecules required to be adsorbed at the newly created surfaces. Thus, 
the emulsion activity will depend on the emulsifier concentration in the bulk (15). 
Figure 6.4 illustrates that the emulsion activity of each emulsifier increases with 
the increase in concentration; however, the differences in emulsion activity among the 
three emulsifiers are slight. 
Emulsion stability 
Emulsions are thermodynamically unstable systems, so after homogenization 
dispersed globules tend to flocculate or coalesce into aggregates or larger droplets. The 
increase in particle size facilitates the upward movement of the dispersed oil and the 
conductivity increases with time. The capacity of an emulsifier to stabilize an emulsion 
depends on both its concentration as well as its mechanism of stabilization. Adsorption of 
protein at the oil-water interface does not always lead to a stable emulsion; the protein 
must form a rigid interfacial layer. A thick layer of protein around the droplet will inhibit 
the thinning required to allow coalescence. Thick layers are likely to be mechanically 
strong, and they are also likely to prevent the close approach of particles through steric 
stabilization. Intuitively, a protein which makes strong contacts with its adsorbed 
neighbors will form a stronger layer than one which does not (1). 
The slope of the linear portion of the conductivity curve after homogenization was 
observed to decrease with an increase in concentration (Figure 6.3). The effect of 
concentration on the rate of change in conductivity after homogenization is much more 
dramatic in the case of nisin than for Tweene 80 and B-casein. At a nisin concentration of Figure 6.4. Effect of concentration on emulsion activity at neutral pH. 
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0.1 mg/ml, the conductivity was about equal to that before emulsification in less than 30 
s, consistent with a highly unstable emulsion. But, emulsions stabilized by nisin showed 
only slight increase in conductivity after homogenization at 5 mg/nil relative to Tween® 
80 and 13-casein, and almost no increase in conductivity after homogenization at 10 
mg/ml. The plots of emulsion stability vs. concentration (Figures 6.5a and 6.5b) are 
consistent these qualitative conclusions. It is not surprising that low concentrations of 
nisin do not form as stable an emulsion as low concentrations of the known emulsifiers 
(casein and Tween 80®). It is surprising the high concentration of nisin form more stable 
emulsions than equal concentrations of casein or Tween 80 ®. 
A schematic of the nisin molecule is given in Figure 5.1. Nuclear magnetic 
resonance (NMR) has been used to show that nisin adopts a kinked but rod-like 
conformation in DMSO (16). Modeled as a cylinder; the overall dimensions of the 
molecule are about 5 nm x 2 nm (8). Van de Ven et al. (17) reported that nisin consists 
of two domains: the first is comprised of residues 3-19 and includes the first three 
lanthionine rings, and the second consists of the coupled ring system formed by residues 
23 to 28. The two domains are connected by a flexible "hinge" region around methionine 
21. Nisin has an amphiphilic character, with a cluster of bulky hydrophobic residues at 
the N-terminus and hydrophilic residues at the C-terminal end (17). The structural 
features of nisin now suggest that upon emulsion formation, its hydrophobic part can 
penetrate the oil, while its hydrophilic part would extend away from the interface into the 
bulk. 
Rigid film formation at the oil-water interface, with steric and electrical 
stabilization of the dispersed droplets may explain the high emulsion stabilizing capacity Figure 6.5a. Effect of concentration on emulsion stability at neutral pH. 
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of nisin at high concentration. In contrast, the inability of nisin to stabilize emulsions at 
low concentration may possibly be due to incomplete coverage of the oil droplets. 
Image analysis 
Dispersed oil droplets stabilized by Tween® 80 and 13-casein were spherical under 
the microscope (Figures 6.6b and 6.6c). In the case of nisin at neutral pH, deformed oil 
droplets were observed in addition to the spherical ones. Under acidic conditions, nisin 
produced mostly spherical oil particles. The size of the deformed droplets ranged from 
about 2-4 gm (Figure 6.7a) to less than 0.5 gm (Figure 6.7b). 
Magdassi and Vinetsky (18) studied the interaction of SDS and gelatin, and 
suggested the formation of an insoluble complex between these two components played 
the major role in microencapsulating oil-in-water emulsions. They stated that irregularity 
in droplet shape is a result of formation of a semisolid phase around the droplets. They 
found that the semisolid phase formed at specific SDS:gelatin concentration ratios and 
pH ranges. Accordingly, deformation of the oil droplets by nisin might be consistent with 
nisin associating with the oil and aqueous phases in a way to form a semisolid or gel-like 
structure. The percentage of nisin-stabilized spherical droplets present in an emulsion 
(Figure 6.6a) increased with increasing nisin concentration, indicating that any semisolid 
phase would be less likely to form at high nisin concentration. Samples from the oil-rich, 
separated, layer were examined under the microscope as well. At a nisin concentration of 
0.1 mg/ml, a gel-like structure (Figure 6.8a) was observed. No gel-like structure was 
observed at higher concentrations, which is consistent with the thought that a semisolid 
phase is less likely to form at high interfacial concentrations of nisin. 105 
Figure 6.6. Spherical oil droplets stabilized by: a) nisin; b)13-casein; and c) Tween® 80. 
Emulsifier concentration is 10 mg/ml. pH = 7.4. The bar shows 20 gm. 
a) 
b) 
c) 106 
Figure 6.7. Deformed oil droplets stabilized by nisin at: a) 5 mg/ml; and b) 10 mg/ml. pH 
= 7.4. The bar shows 201.1.m. 
a) 
b) 107 
Figure 6.8. Aggregated oil droplets stabilized by: a) nisin; b)13-casein;c) Tween® 80. 
Emulsifier concentration is 0.1 mg/ml.pH = 7.4. The bar shows 20 gm. 
a) 
c) 108 
Emulsions stabilized by nisin were examined for the presence of liquid crystals in 
polarized light; no optical pattern was seen. Samples from the oil-rich layer appeared as 
highly aggregated spherical particles when Tween® 80 or 13-casein was used (Figures 8b 
and 8c). 
Deformation is frequently encountered and leads to a reduced sediment or cream 
volume (19). The more rigid the interfacial film, the greater the resistance to deformation. 
On the other hand, the greater the size of the droplets and the density difference between 
the two liquid phases, the greater the tendency for deformation to occur (19). Oil droplets 
can distort into polyhedral "cells", resembling a foam in structure. This would result in a 
network of more-or-less planar thin films of one liquid separating cells of the other liquid 
(19). The stability of the system to coalescence would then depend on the stability to 
rupture of these films. At high nisin concentration, a continuous, rigid adsorbed film and 
small particle size may explain the increasing tendency of dispersed oil droplets to be 
spherical. 
Particle size was not affected by Tween® 80 or 13-casein concentration. The reason 
for this might be related to the relatively low stability of these emulsions. Even at the 
highest concentration tested, the shortest time required to prepare and examine a sample 
for particle size was greater than the magnitude of emulsion stability. 109 
Effect of concentration on the emulsifying activity of nisin at acidic pH 
Nisin stability, solubility and antibacterial activity are highly pH dependent; they 
decrease as the pH is increased (20). Therefore, the effect of pH on the emulsifying 
activity of nisin was studied. Figures 6.9a and 6.9b show that, contrary to what was found 
at neutral pH, the effect of nisin concentration on emulsion stability under acidic 
conditions is slight. They also show that with concentrations tested, nisin gives less stable 
emulsions than Tween® 80. 
Because the net charge of a protein is least near its isoelectric point, it may be 
hypothesized that hydrophobic interactions between the protein and the oil surface would 
be less inhibited (1). Nisin has an isoelectric point in the alkaline range; thus, the net 
charge on its surface should be higher at acidic pH than at neutral pH. In addition, the 
decrease in nisin solubility with increasing pH indicates that hydrophobic associations are 
more favorable at neutral pH. Net charge may also affect the adsorbed mass by repulsion 
between adsorbed and adsorbing molecules at the interface. The adsorption of nisin to 
bacterial cells is pH-dependent (21), with a maximum in adsorption observed at pH 6.5, 
and less than half of that being adsorbed at pH 4.4 (22). The ability of nisin to form pore 
structures in the bacterial cell membrane depends on its ability to aggregate after 
adsorption. The higher antimicrobial activity of nisin at acidic pH than at neutral pH 
would suggest that self assembly is more favored at acidic pH. If we assume that the 
effect of pH on the aggregation of nisin molecules at the oil-water interface is similar to 
that at a bacterial cell membrane, fewer nisin molecules would be in monomeric form 
after adsorption at acidic than at neutral pH. Figure 6.9a. Effect of concentration one emulsion stability at pH 5.2. 
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CONCLUSIONS
 
Emulsion conductivity measurements  is  a valuable tool  to measure the 
emulsifying activity of surfactants. Nisin is an amphiphilic polypeptide with high surface 
activity. Nisin has high ability to stabilize oil in water emulsions in comparison to Tween 
80 and 13-casein. The emulsifying activity of nisin is highly concentration and pH 
dependent. It increases sharply with increasing concentration and pH. Adsorption of nisin 
into oil water interface can deform the structure of the dispersed oil droplets in oil in 
water emulsion, which might be due to gel formation. 113 
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CHAPTER 7 
INTERFACIAL TENSION KINETICS OF NISIN AND B-CASEIN AT
 
AN OIL-WATER INTERFACE
 116 
ABSTRACT
 
The concentration- and time-dependence of interfacial pressure of nisin and 13­
casein at an n-hexadecane-water interface were evaluated using Du Notiy tensiometry. 
The two emulsifiers attained interfacial saturation at  a bulk concentration of about 0.1 
mg/ml, the reduction of the interfacial tension by nisin at that concentration being about 
equivalent to that of 13-casein. The time dependence of interfacial tension recorded for 
each protein was described using two kinetic models. In the first, the reduction of 
interfacial tension with time was considered to be a result of molecular penetration into 
the interface followed by rearrangement. Nisin exhibited  more rapid penetration and 
rearrangement at the interface than did 13-casein. The second model allowed for the 
parallel, irreversible adsorption of protein into each of two states from solution, where 
state 2 molecules occupy a greater interfacial area and are more tightly bound than state 1 
molecules. The extent of adsorption in state 1 and state 2 was determined to be highly 
concentration dependent for each protein; adsorption occurs mostly in state 1 at high 
concentration and mostly in state 2 at low concentrations. The effect of pH on interfacial 
activity of nisin was also studied and it was found that the interfacial activity  of nisin 
decreases with decreasing pH. 117 
INTRODUCTION
 
Proteins adsorb at air-water and oil-water interfaces, decreasing interfacial 
energy. The rate and extent of this decrease depend on many factors, including the size, 
charge, and flexibility of the adsorbing protein (1). Fluid interfaces differ from solid 
interfaces in allowing adsorbate molecules greater mobility at the interface and  greater 
penetration into the nonaqueous phase (2). Thus, studying protein adsorption at gas-liquid 
and liquid-liquid interfaces is important for proper understanding of the ability of proteins 
to stabilize emulsions and foams in a variety of applications (2-7). Graham and Philips 
(1) suggested that, native molecules must first penetrate the air-water  or oil-water 
interfaces, then unfold and rearrange for optimal packing. They also stated  that 
adsorption is controlled by diffusion, a function of the size of the molecule. Thus, at low 
surface coverage, every protein molecule that  arrives  at the  interface  adsorbs 
spontaneously. Eventually, a steady state is achieved when the interface is saturated, and 
all of the molecules have rearranged to their preferred orientation (1,3). 
The adsorption of proteins at air-water interface was described by a model that 
allows for tight adsorption of a first layer and loose packing of a second layer (4); in the 
first layer, protein adsorbs in different conformations with different occupied areas per 
adsorbed molecule, dependant upon surface concentration. Cho et al. (5) reported that the 
native and alkylated derivatives of bovine serum albumin occupy greater area at the air-
water interface than that corresponding to molecular dimensions. They also found that the 
rate of surface pressure increase for these proteins was higher for higher bulk 
concentration at low times. In the classical 2-state theory of the globular  protein 
unfolding transition (2), there are two protein structures: native and highly disordered. 118 
However, it has now been established that an intermediate conformation can be present, 
termed the "molten globule", defined as a protein with a native-like secondary structure 
but disordered (unfolded) tertiary structure (2). It was found that a-lactalbumin in the 
molten globule state (produced in the presence of EDTA) reduced the surface tension at 
the air-water and n-tetradecane-water interfaces more rapidly and to a lower level than 
the native protein (2). For globular proteins at the air-water interface, Farooq and 
Narsimhan (6) proposed that adsorbed segments are present in the form of "trains". They 
concluded that the degree of unfolding of bovine serum albumin upon adsorption was 
greater than that of lysozyme, as they found that the number of segments per molecule 
increased linearly with the increase of surface concentration for bovine  serum albumin, 
and was independent of surface concentration for lysozyme. Other studies suggested that 
protein molecules undergo conformational change during the adsorption process due to 
the interaction with the surface or during overcoming energy barrier to adsorption (8,9). 
In particular, free energy change of a protein molecule for conformational change to  a 
denatured foim, 5 to 14 kcal/mol, is comparable to the free energy for adsorption, 5 to 20 
kcal/mol. Thus, the conformational change during adsorption is highly probable. 
13-casein is a single chained, fibrous protein of molecular weight 24,000 that has 
no disulfide bonds (7). The N-terminal 21-amino acid sequence of 13 -casein contains one-
third of the charged residues at pH 7, and this portion of the protein is highly solvated and 
flexible. The remainder of the molecule is nonpolar and very hydrophobic, making 13­
casein distinctly amphiphilic (7). Hunter et al. (7) modeled the adsorption of 13 -casein at 
the air-water interface using Langmuirian kinetics, defining an adsorption activation 
energy that depends on surface coverage. They found the isotherm exhibited two plateaus 119 
in surface coverage. The isotherm was interpreted as indicating adsorption of a saturated 
layer of f3- casein at low concentration followed by molecular reorientation and continued 
adsorption until the surface is once again saturated. 
Nisin is a polypeptide (3510 Da) consisting of 34 amino acid residues (10). As far 
as the amino acid sequence is concerned, nisin possesses an amphiphilic character, with a 
cluster of bulky hydrophobic residues at the N-terminus and hydrophilic residues at the 
C-terminus (10). Nisin can withstand activity loss during thermal processing and 
exposure to acidic environments and pressure extremes (11). These characteristics and 
others, such as non-toxicity, high surface activity and antimicrobial activity (12) make it 
an attractive candidate for use as an emulsifier in food and pharmaceutical emulsions. 
The efficacy of nisin in emulsifying oil in water was evaluated (13) and found to be 
significant compared to 13-casein and Tween® 80. The interfacial behavior of nisin and (3­
casein at hydrophilic and hydrophobic solid surfaces has been investigated using 
ellipsometry (14,15). Each of the proteins, when dissolved in single-protein solution, 
more favorably adsorbed at hydrophilic than at hydrophobic surfaces. 
In this work, we evaluated the interfacial tension kinetics of nisin and B-casein at 
n-hexadecane-water interface using Du Noily tensiometer. In order to account for the 
effect of conformational change during adsorption, the interfacial tension kinetic data of 
each protein were analyzed with reference to a two state mechanism that allows for 
protein to adsorb in structurally dissimilar forms. 120 
MATERIALS AND METHODS 
Materials 
Pure nisin (about 5.0 x 107 IU/g) was obtained from Aplin and Barrett Ltd. 
(Dorset, U. K.). Tween® 80 (Lot No. 44H01211), n-hexadecane (Lot No. 105H3530) and 
13-casein (Lot No. 25H9550) were purchased from Sigma Chemical Co. (St Louis, MO). 
Monobasic sodium phosphate monohydrate (Lot No. 77892KLJP), dibasic sodium 
phosphate heptahydrate (Lot No. 7914KJKA) and citric acid monohydrate (Lot No. 
062777KMBX) were obtained from Mallinckrodt Specialty Chemical Co.  (Paris, 
Kentucky). Sodium citrate (Lot No. 402346) was from J.T. T. Baker (Philipsburg, NJ). 
Solution preparation 
Nisin was dissolved in 0.01 M sodium phosphate monobasic (pH 4.5), to assure 
complete solubilization. A suitable volume of sodium phosphate dibasic (pH 9.1, 0.01 M) 
was added to the solubilized nisin to bring the pH to 5.5, 6.5 or 7.4. Nisin solutions of pH 
3.0 and 4.5 were prepared using citrate buffer (0.01 M). The same buffers were used to 
prepare 13-casein and Tween® 80 solutions. 
Interfacial tension measurement 
A Du Noily ring tensiometer (Model No. 70535, CSC Scientific Co., Inc., Fairfax, 
VA) was used to measure interfacial tension at the n-hexadecane-water interface. 
Immediately after gentle stirring for 45 s, 20 ml of emulsifier solution at a concentration 121 
in the range of 1 x 10-6 to 1 mg/ml, was placed in a beaker (5 cm dia). The ring was 
immersed about 10 mm below the surface of the  emulsifier solution, and this was 
followed by the addition of 20 ml n-hexadecane to the surface of the solution. The 
position (height) of the beaker was adjusted until the ring was in the interface and the 
apparent interfacial tension was measured (7). To account for the force needed to support 
the weight of the liquid clinging to the ring at the break point, the apparent interfacial 
tension was multiplied by a correction factor to get the true interfacial tension. All 
performed  at  room  temperature  (23-25°C).  Before  each measurements  were 
measurement, the ring was cleaned by rinsing  in benzene followed by rinsing in 
methylethylketone, and then heating in the oxidizing portion of the flame of an alcohol 
burner. 
Interfacial pressure 
Interfacial pressure, II (mN/m), is the reduction of interfacial tension by a 
surfactant. The average of three interfacial tension readings between phosphate buffer 
(pH 7.4) and n-hexadecane was 52.4 mN/m. The interfacial pressure was obtained by 
subtracting the interfacial tension in the presence of a surfactant from this value. 122 
RESULTS AND DISCUSSION 
Effect of concentration on steady-state interfacial pressure 
The concentration dependence of IT for nisin, 13-casein and Tween® 80 is shown 
in Figure 7.1. Each emulsifier showed an increase in  II  with increasing bulk 
concentration. The maximum reduction in interfacial tension was 42.2, 32.2 and 30.4 
mN/m for Tween® 80,13-casein and nisin, respectively. 
Gibbs adsorption equation can be used to calculate the  surface  excess 
concentration of an amphiphile. Applying Gibbs equation to  protein adsorption is 
completely empirical, because molecules can do more than one point of attachment at an 
oil-water interface, and the area occupied by a single protein molecule can vary according 
to the interfacial concentration. It is of some qualitative interest, however, to apply the 
simple form of Gibbs adsorption equation to gain an expression for the surface excess 
concentration of a protein (I', mol/m2). That is, assuming adsorption equilibrium and that 
the activity of protein at the interface equals its concentration in the bulk, the equation 
can be written as (16) 
[1] = (Cp/RT) 5 (dff/dCp), 
where R and T are the universal gas constant and absolute temperature, respectively. The 
change of spreading pressure with concentration can be fitted according to the following 
equation 
[2] II = Al In (1 + A2Cp). 45 
Figure 7.1. Effect of concentration on interfacial pressure. 
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Eq. [2] represents a model with two function parameters Al  (mN/m) and A2 
(ml/mg). Suttiprasit et al (17) applied Eq. [2] to IT Vs concentration data of the proteins 
a-Lactalbumin, 13-Lactoglobulin and Bovine Serum Albumin. The values of Al and A2 
estimated for nisin, 13-casein and Tween 80 along with the coefficient of determination 
(R2) for each fit to Eq. [2] are listed in Table 7.1. 
Table 7.1. Model parameter values estimated for Tweene 80,13-casein and nisin using Eq. 
[2]. 
Surfactant  Al (mN/m)  A2 (ml/mg) x 10-6  R2 
Nisin  2.14  3.49  0.987 
Tweene 80  3.34  0.64  0.995 
13- Casein  2.39  1.28  0.996 
Substitution of Eq. [1] into Eq. [2] yields 
F = (Ai/RT)[(A2Cd414-A2Cp)]  [3] 
The adsorbed masses of the three emulsifiers were calculated  according to Eq. [3] and 
listed in Table 7.2. The higher the value of Al and A2 of a surfactant, the higher the 
saturation of the interface is attained with increasing bulk concentration.  According to 
Table 7.2, nisin gives more saturation of the interface with increasing concentration than 
Tween® 80 or 13-casein. 125 
Table 7.2. Adsorbed mass (pmole/cm2) at oil-water interface calculated according to Eq. 
[31. 
Adsorbed mass (pmole/cm2) 
Concentration (mg/ml)  Nisin  13-Casein  Tween® 80 
10-6  67.30  54.26  52.71 
10-5  84.15  89.58  116.57 
10o  86.31  95.81  132.64 
10-3  86.53  96.49  134.49 
10-2  86.56  96.55  134.68 
0.1  86.56  96.56  134.70 
0.5  86.56  96.56  134.70 
1  86.56  96.56  134.70 
Time dependence of surface pressure 
Empirical analysis 
Figures 7.2, 7.3 and 7.4 show time dependence of ri for Tween® 80, 13-casein and 
nisin (solid lines for the higher concentration data of nisin and 13-casein represent fits to a 
model that will be discussed in the next section). The three emulsifiers attained a steady 
state interfacial pressure, at all concentrations, after about 2 hours. For single protein 
solutions of13-casein, BSA and lysozyme, Graham and Philips (1) suggested that the rate Figure 7.2. Time dependence of interfacial pressure for nisin as a function of concentration. 
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of change of interfacial pressure can be defined with reference to two kinetic regions, 
each characterized by a first-order rate constant. The first region, the adsorption period, is 
one in which both adsorbed mass and interfacial pressure are observed to increase. The 
other region, the rearrangement period, is characterized by attainment of a plateau in 
adsorbed mass while the interfacial pressure continues to increase. Small emulsifiers, 
such as Tween® 80, can do further orientation at the interface after adsorption to optimize 
the hydrophilic and hydrophobic interactions, which results in a gradual reduction in 
interfacial tension with time (18). Caseins, particularly 13-casein, possess relatively small 
amounts of regular structure, and are conformationally mobile, enabling them to readily 
optimize their configuration at the interface.  In addition, they possess extensive 
hydrophobic regions (as can be estimated from their secondary structure), which are 
likely to act as the points of attachment to the interface (19). Globular proteins must 
denature in order to optimize their interaction (19). Also, adsorbed proteins can interact 
with each other through intermolecular bonds (H-bonds, salt bridges, and disulfides) 
which are not possible for small molecules (19). Rates of adsorption and conformational 
change can be represented by the first order equation: 
In (n00-llt) /n0 -no = -kt,  [4] 
where IL, lit and no are the surface pressure values at steady state, at any time t, and at t 
= 0, respectively, and k is a first-order rate constant. In order to get an accurate estimate 
of the rate of penetration and conformational change. Eq. [4] should be applied in the 
absence of diffusion control. Graham and Philips (1) reported that at a bulk concentration 130 
of 0.001 mg/ml, changes in II for BSA were diffusion controlled for about 1 hr. After this 
period, the surface coverage was such that an energy barrier to adsorption made the rate 
of adsorption lower than that predicted by the rate of diffusion. When the rate of 
adsorption equals the rate of diffusion, the total surface concentration of molecules can be 
estimated by 2C1, (Dt/I1)1/2, where D is the diffusion coefficient. At 0.1 mg/ml, adsorption 
should be diffusion controlled for much less than 5 minutes, which was the time for the 
first interfacial tension measurement in this study. Fitting the interfacial kinetic data 
according to Eq. [4] usually yields more than one linear segment. The slope of the first 
linear segment is considered as an adsorption rate constant, while the slope of the second 
or third segment is interpreted as a rearrangement rate constant. 
Figure 7.5 shows that each emulsifier has two distinct linear regions. The first-
order rate constants estimated in each region, along with the coefficient of determination 
for each line, are shown in Table 7.3. 
Table 7.3. First order constants associated with adsorption (kg) and rearrangement or 
conformational change (lcd. 
Emulsifier  k1 (10-2min-1)  k2 (10-2mid1) 
Nisin  73.64 (1.00)  1.23 (0.93) 
13- Casein  18.29 (0.754)  0.322 (0.749) 
Tweee 80  82.59 (1.00)  0.538 (0.92) 
Note. The coefficients of determination estimated for each line 
are shown in parenthesis. Figure 7.5. Interfacial pressure data plotted according to Eq. (6). 
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The order of penetration rate constant of the three emulsifiers is Tween® 80 > 
nisin > 13-casein. The rate of adsorption of a molecule from the bulk into interface is 
controlled by its size, hydrophobicity and concentration. The increase in concentration 
and hydrophobicity results in an increase in adsorption rate, while as the molecular size 
increases the adsorption becomes slower (1). Tween® is a small emulsifier with a 
molecular weight of 1,309.68, while 13-casein is a giant protein with a molecular weight 
of 24,000 and is known to form aggregates in aqueous solution, particularly at high 
concentrations. Nisin is a polypeptide with molecular weight of 3,510, however, there is 
an evidence that dimers and tetrameters occur having weights of 7,000 and 1,4000 
(20,21). 
Table 7.3 shows that nisin can achieve stable film at an oil-water interface much 
faster than 13-casein and Tween® 80. A schematic of the nisin molecule is given in Figure 
5.1. Van de Ven et al. (22) reported that nisin consists of two domains: the first is 
comprised of residues 3-19 and includes the first three lanthionine rings, and the second 
consists of the coupled ring system formed by the residues 23 to 28. The two domains are 
connected by a flexible "hinge" region around methionine 21. Nisin has an amphiphilic 
character, with cluster of bulky hydrophobic residues at the N-terminus and hydrophilic 
residues at the C-terminal end (22). The presence of a flexible "hinge" between 
hydrophilic and hydrophobic domains of nisin together might allow for rapid hydrophilic 
and hydrophobic associations at an oil-water interface. 133 
Analysis with reference to a kinetic model 
Wang and McGuire (23) applied a kinetic model to describe the spreading 
pressure of T4 lysozyme solutions, allowing protein to be adsorbed structurally and 
functionally dissimilar. State 2 molecules are unfolded to some extent and more tightly 
bound to the surface than those in state 1; also the area occupied by a state 2 molecule 
(A2) is larger than that occupied by a state 1 molecule (A1). The same adsorption 
mechanism can be applied to protein adsorption at an oil-water interface, and is 
illustrated in Figure 7.6. Rate constants k1 and k2 describe adsorption into state 1 and 
state 2 respectively. Neglecting the influence of diffusion, equations describing the time-
dependent fractional surface coverage of protein in each of the two states (01 and 02) 
shown in Figure 7.6 can be solved, such that 
01=11(1+ ak21 ki)[1 - exp(- IciC - ak2C)J  [5] 
and 
02 =Kk2 1 ki)1(1+ ak21 OF- exp( kiC - ak2C)/1,  [6] 
where a is A2 / A, and C (mg/ml) is the bulk protein concentration. 134 
Figure 7.6. A simple mechanism for protein adsorption at an oil-water interface. 
At  02  oil 
water 
Defining F.. as the maximum adsorbed mass of molecules allowable in a 
monolayer, and 01 and 02 as mass of state 1 and state 2 molecules (mg/m2) adsorbed at 
any time, respectively, divided by  the adsorbed mass of molecules allowable in a 
monolayer in at any time, F (mg/m2), can be given by 
F = F.,(A +  , 
and when the surface is covered, 
A + a02 = 1 .  [8] 
The contribution of reduction in interfacial tension is different between state 1 and 
state 2; more reduction per interfacial area unit is attained with the adsorption in state 2. 
Hi and 112 are defined as the interfacial pressure when the interface is covered entirely by 
state 1 and state 2, respectively, and b is 111/112. The maximum interfacial pressure 135 
measurable would correspond to a monolayer of state 2 molecules; i.e., -max = = II 2  Hi. 
The interfacial pressure at any time is therefore given by 
II=  (b 01+ a02).  [9] 
A model for the spreading pressure at any time can be obtained by substituting 
Eqs. [5] and [6] into Eq. [9]: 
H.1-14(b -Fak2 / ki) / (1+ aka / kill x [1 exp(kiC ak2C)t J.  [10] 
In order to solve for kiC and k2C in Eq. [10], the values of a, H. and b should 
be known or approximated. McGuire et al.  (24) estimated the fraction of state 2 
molecules present in a monolayer formed on hydrophobic silica (i.e.,  8a/(01 +82), 
evaluated at steady state) for wild type T4-lysozyme, and the mutants 13 and I3W. In a 
related study, Wang and McGuire (23) assumed air-water interface as an ideal 
hydrophobic surface and the fraction of state 2 molecules estimated for these proteins at 
hydrophobic silica to be similar to that at the air-water interface. They calculated rImax 
and b of these mutants using Eq. [10] applied at steady state. Because we did not have 
mutants for raisin or 13-casein, b values of both proteins could not be calculated. If we 
assume as a first approximation that adsorption in states 1 or 2, while occupying different 
interfacial areas, would result in the same interfacial tension reduction, Eqs. [9] and [10] 
become 136 
II= Ilmax(611+ 02), 
and 
1-1  + k2 / ki) /(1 + ak2 I Ici)] x[1 exp( kiC ak2C)t],  [12] 
respectively. 
Based on molecular dimensions, 20 5 20 5 50 A for nisin (23) and 14.6 5 14.6 5 
175 A for 13-casein (7), the parameters Al and A2 can be estimated as the interfacial area 
occupied by adsorbed " end on" and "side on" molecules respectively, such that a is 2.50 
for nisin and 11.99 for 13-casein. The maximum measured reduction in interfacial tension 
(32.2 for13-casein and 30.4 for nisin) provide an estimate for the theoretical 
The values of k1C and k2C for nisin and 13 -casein were estimated according to Eq. 
[12] and are listed in Table 7.4. In general, we can see that the rate of adsorption in state 
1 decreases with decreasing concentration, while the rate of adsorption in state 2 
increases with decreasing concentration. At high bulk concentration, the ratio of the 
interfacial area to the total number of molecules available for adsorption is very small, 
and saturation of the interface is attained in a very short period of time. This suggests that 
the sub-layer would be crowded, with only little uncovered interface being available as 
adsorption progresses. Alternatively, the possibility for a protein molecule to extend its 
conformation and be adsorbed in state 2 would be maximized in a dilute solution. 137 
Table 7.4. Rate constants k1C and k2C, based on a calculated from molecular dimensions 
and fitting interfacial pressure kinetic data to Eq. [12]. 
Concentration (mg/ml)  Nisin  13-Casein 
k1Ca  k2Ca  kiCa  k2Ca 
1  50.952  0.687  38.019  0.060 
0.5  50.001  2.164  33.378  0.057 
0.1  50.591  0.405  31.197  0.069 
0.01  41.991  5.947  28.477  0.263 
0.001  6.388  9.340  11.290  0.645 
0.0001  1.972  2.518  0.413 
0.00001  1.518  1.984  0.810 
0.000001  1.011  0.755  0.410 
a  ml/mg.min 
- Negative value was obtained. 
An experimentally determined "a" may allow for more accurate estimation of 
adsorption in states 1 and 2 using Eq. [12] than what was estimated using the molecular 
dimensions. The isotherms of the steady-state interfacial pressure versus the bulk 
concentration (Figure 7.1) appear to be sigmoidal with upper and lower critical 
concentration. The interfacial pressure does not change very much below the lower 
critical concentration, probably because adsorption occurs only in state 2. The lower 
critical concentrations were specified as 1 5 104 mg/ml for nisin and 1 5 104 mg/ml for 
13- casein. We assume that adsorption below these critical concentrations occurs in state 2 
only, such that 138 
d82 = k2C[1 a02] ,  [13]
dt 
or 
H = H my/ a[1 exp(k2 I a)Ct].  [14] 
a values obtained from Eq. [14] at the lower critical concentration (4.183 for 13­
casein and 3.718 for nisin) were used in estimating k1C and k2C for the two proteins 
according to Eq. [12] at concentrations higher than the lower critical concentration. The 
interfacial tension kinetic data, along with their fit to Eq. [12], are shown in Figures 7.1 
and 7.2. The plots of k1C and k2C versus log concentration for both proteins (Figures 7.7 
and 7.8) are consistent with the tendency for more adsorption in state 2 with the decrease 
in concentration. Figures 7.9 and 7.10 show that k1 and k2 decrease with increasing 
concentration. Guzman et al. (4) modeled the dependence on surface concentration for 
adsorption rate constants in terms of activation energies for adsorption and desorption. 
Accordingly, k1 and 1c2 might be best represented in the form ki = kio exp(-EdRT), where 
Ea, the activation energy for adsorption, is considered to be surface coverage dependent. 
The results in our study suggest that the activation energy for protein adsorption 
increases with increasing surface concentration of nisin and 13-casein; consequently, the 
ease with which a protein molecule adsorbs should decrease with increasing surface 
concentration. Hunter et al. (7) found that for 13-casein, at low concentrations (<10-3 
mg/ml), adsorption at air-water interface was "cooperative" becoming easier as the Figure 7.7. Adsorption rates k1C and k2C (ml /mg.min) for nisin as a function of 
concentration, based on fitting interfacial pressure kinetic data recorded to Eq. [12]. 
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surface coverage increased, while at higher concentrations NO mg/ml), adsorption 
became more difficult as the surface coverage increased. 
At steady state, Eq. [10] becomes 
= ri.[(b ak2/10/(1 + ak2I ki)].  [13] 
Under some conditions, values of k1C and k2C estimated from Eq. [13] might not be very 
different from what can be estimated using Eq. [12]. This would be particularly true at 
high concentrations, at which b is expected to be close to 1 and k2/k1 is very small. 
Accordingly, b can be roughly estimated by substituting k1C and k2C obtained from Eq. 
[8] into Eq. [11]. b-values obtained for nisin and 13- casein are listed in Table 7.5. 
Table 7.5. b values based on assuming Eq. [13] to be equivalent to Eq. [12] at steady 
state. 
Concentration (mg/ml)  Nisin  13 -Casein 
1  1.000  1.000 
0.5  0.985  0.994 
0.1  0.944  0.998 
0.01  0.808  0.913 
0.001  0.360 
0.0001 
- Negative vlaue was obtained 
Negative b-values were obtained for the fitted data of each protein at the lowest 
concentration. This might be due to the shortcomings of the assumptions that allowed for 144 
the estimation of adsorption rates. The areas of state 1 and 2 might not be constant with 
changing concentration. 
The two  states  mechanistic model might not work well  at  very low 
concentrations, due to the fact that adsorption from highly diluted solution is transport-
limited process; i.e., the rate of diffusion to the surface is slower than the rate of protein 
binding to the surface (24). In addition, protein adsorption at such low concentrations 
might not result in complete coverage of the interface at steady state. In addition, 
adsorption rate constants might not be constant during the entire adsorption period; as 
surface coverage increases, the energy barrier to adsorption may also increase (24). 
Modeling of protein adsorption in two states allows for better understanding and 
quantification of the effect of bulk concentration on conformational changes of proteins 
at interfaces and more accurate prediction of their behavior when present in a mixture, 
such as competitive adsorption and desorption.  All this  is important for better 
understanding of any process or system that involves contact between some material and 
protein-containing fluid, such as emulsions, membrane-based separation, adsorption-
based recovery of proteins and peptides in downstream processing, and any operation 
susceptible to bacterial attachment and biofilm formation. 
Effect of pH on interfacial pressure of nisin at oil-water interface 
Figure 7.11 shows that, compared to Tween® 80 (a nonionic surfactant), nisin 
interfacial activity is reduced as the bulk solution is more acidic. Generally, the greater 
the reduction in interfacial tension, the stronger the surfactant property of protein. This 
correlates very well with the functional hydrophobicity (19). Nisin exhibits lower Figure 7.11. Effect of pH on interfacial pressure. 
-4- Nisin
 
-- Tween 80
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hydrophobicity, with the reduction of pH. The adsorption of nisin at bacterial cells 
is pH dependent (25), with a maximum adsorption at pH 6.5, and less than half of that 
being adsorbed at pH 4.4 (26). Accordingly, the low interfacial activity of nisin in acidic 
conditions might be due to low adsorbed mass, poor hydrophobic association with the oil 
phase or both. These results were expected, as it was found that nisin exhibits higher 
emulsifying activity at neutral than acidic pH (27). 
CONCLUSIONS 
Nisin, in comparison to f3-casein and Tween 80, can adsorb at oil water interface and 
reduce the interfacial tension significantly. Modeling of the interfacial tension data of 
nisin and 13-casein at an oil water according to a model that allows for adsorption in two 
dissimilar states, has shown that adsorption at high concentrations occurs in extended 
form and at low concentrations in compacted form. The model was limited with the 
assumptions of the same reduction of interfacial tension per unit surface area by the two 
states, and no effect of diffusion on adsorption, which might be significant at very low 
concentrations. 147 
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CHAPTER 8 
EFFECT OF NISIN ON ERYTHROCYTES, AND DRUG RELEASE
 
FROM OIL-IN-WATER EMULSIONS
 150 
ABSTRACT 
Nisin is a polypeptide (3510 Da) antibacterial substance produced by the 
fermentation of a modified milk medium by certain strains of the lactic acid bacterium, 
Lactococcus twits. It shows antimicrobial activity against a range of Gram positive 
bacteria, particularly spore formers. The hemolytic effect of nisin on red blood cells was 
studied. RBCs hemolysis was measured as the increase in UV absorbance as a result of 
hemoglobin release. Nisin did not hemolyse red blood cells at concentrations less than 
0.15 mg/ml, but at higher concentrations hemolysis increased linearly and significantly 
with increasing concentration. Drug release from oil-in-water emulsions stabilized by 
nisin was studied and compared to that from emulsions stabilized by Tween® 80. It was 
found that nisin retards drug release from oil-in-water emulsions. 151 
INTRODUCTION
 
Nisin is a cationic polypeptide secreted by some lactic acid bacteria. It possesses 
antimicrobial activity against a broad spectrum of Gram positive bacteria and has realized 
commercial application as a food preservative (1). Nisin is  a highly surface active 
molecule whose adsorptive properties were recognized as early as 1949 when it was 
noted that nisin in culture remained with Lactococcus lactis cells rather than in the 
culture broth at pH 6 (2). Nisin has been considered to produce the same effect as a 
cationic, surface-active compound with a detergent effect on the bacterial cell membrane 
because leakage of UV absorbing material from treated bacterial cells was observed (3). 
Nisin is reported to not hemolyse sheep or human erythrocytes (4). These results 
were expected as the threshold potential required for nisin to induce pore formation in 
cytoblasmic membranes, at pH 7.5, is 50 mV (5), while the membrane voltage of 
erythrocytes is -10 mV (4). 
Nisin was found to form a gel-like structure at oil-water droplet interfaces (6). As 
a result, deformed particles of oil-in-water emulsions stabilized by nisin were observed 
under the microscope. Accordingly, nisin as an emulsifier might affect the release ofan 
emulsified drug species by two mechanisms. The gel structure might retard diffusion 
across oil droplets as a result of high interfacial viscosity. Irregular shape oil droplets has 
higher area/volume ratio than spherical ones. Consequently, enhancement of the release 
rate and extent might be caused by the deformation in oil droplets. Shah et al. (7) 
investigated the efficiency of various types of polyglycolyzed glycerides in self-
emulsifying drug delivery systems by evaluating the rate and extent of drug release. They 
found high correlation between average droplet size of an emulsion and drug release rate. 152 
In emulsions, drugs are absorbed mainly into the aqueous phase; the absolute volume of 
the aqueous phase is critical for poorly oil-soluble drugs (K < 1); the amount of drug in 
the aqueous phase is important for K > 1, where K is the oil-in-water partition coefficient 
of the drug (8). When the initial amount of drug in the  aqueous phase is large in 
comparison with the total amount of drug or when little drug exists in the aqueous phase 
initially, the rate-limiting step for absorption is drug transfer from oil to water rather than 
from oil to membrane (8). Emulsions are more effective for lymphatic delivery than 
aqueous solutions when injected directly into malignant lymphomas. The emulsifier can 
greatly influence the amount of drug bound to oil droplets as demonstrated oil-in-water 
emulsions of mitomycin C, where gelatin (an animal protein)  gave better results than 
polysorbate 80. Gelatin microsphere oil-emulsions showed enhanced and sustained 
delivery of bleomycin in comparison to intravenous and topical injection of aqueous 
solution (8). 
In this study, the effects of nisin on drug release from oil-in-water emulsions and 
red blood cells hemolysis were studied. 153 
METHODS 
Red blood cells hemolysis 
Red blood cells hemolysis was done as described previously (4,9). A 0.7% 
suspension of sheep erythrocytes (SRBC) in phosphate-buffered saline was incubated at 
37 °C for 30 min in the presence of various concentrations of nisin or saponin. 
Erythrocytes were removed by centrifugation and hemolysis was recorded as increasing 
absorbance at 540 nm. 
Drug release studies from oil-in-water emulsions 
USP XXII, Dissolution Apparatus (Van-Kel Industries, Inc.) was employed to 
study the drug release in emulsions. Because it can be easily dissolved in soybean oil and 
assayed by UV, salfasalazine was selected as a model drug. The formulations that were 
tested are shown in Table 8.1. 
The release of salfasalazine from each formulation was tested in 900 ml distilled 
water. Alkamuls EL-719 (HLB = 16, polyoxyethylated (40) castor oil  non ionic 
surfactant from Rhone-Poulenc) was added to dissolution media at concentration of 5% 
to provide sink condition and permit quantitation of the drug release (7). 
Samples were drawn at 5, 10, 15, 30, and 60 min, filtered through 0.2 gm filter 
and then analyzed by UV at 360 nm. For comparison controls, all experiments were 
repeated using the surfactant Tween® 80 in place of nisin. 154 
Table 8.1. Formulation of emulsions. 
Formulation 
Ingredient  I (% w/w)  H (% w/w) 
Salfasalazine  4  4 
Nisin  0.2  0.4 
Soybean oil  40  40 
Distilled water  55.8  55.6 
RESULTS AND DISCUSSION 
Red blood cell hemolysis 
Kasschau et al. (9) measured the hemolytic activity of the adult Schistosome 
mansoni membrane fraction. They measured RBCs hemolysis by assaying the released 
hemoglobin spectrophotometrically at 540 TIM. In this study, hemolysis was measured as 
the increase in absorbance at 540 nm. Compared to saponin, nisin showed insignificant 
hemolytic effect on sheep red blood cells (SRBC) at concentrations less than 0.15 mg/ml 
(Figure 8.1). However, at higher concentrations, SRBC hemolysis was found to increase 
significantly and linearly with increasing nisin concentration (Figure 8.1). Saponin 
showed complete hemolysis of the SRBC at concentration of about 0.05 mg/ml. Defined 
as concentration that hemolyses 50% of SRBC, the hemolytic titer was calculated to be 
0.25 mg/ml for nisin and 0.03 mg/ml for saponin. In a similar study, Kordel and Sahl (4) 
found that nisin in concentrations up to 1 mM (0.0035 mg/ml) increased the UV Figure 8.1. Hemolytic effect on suspended red blood cell. 
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absorbance by only 6 %. In this study, nisin in concentrations up to 0.0313 mg/ml 
increased the UV absorbance by not more than 12%.  Nisin can form pores in 
cytoplasmic membranes, consequently, nisin might only increase the permeability of 
RBCs for intracellular substances without total hemolysis. Microscopical examination 
would be a valuable tool to investigate these effects on RBCs. 
Drug release from oil-in-water emulsions 
Figure 8.2 shows that the release of sulfasalazine is slower from emulsions 
stabilized by nisin than from emulsions stabilized by Tween® 80. This effect was more 
profound at higher concentrations. Nisin has been shown to form a gel-like structure at 
oil-water interface (6). This structure might increase the interfacial viscosity and retard 
the diffusion of drug from the oil phase into the aqueous phase. It is highly unlikely that 
these differences are due to differences in particle size, because nisin at the used 
concentrations produces more stable oil-in-water emulsions than Tween® 80 (7). Figure 8.2. Sulfasalazine release from oil-in-water emulsions. 
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CONCLUSIONS 
Nisin can hemolyze red blood cells, which might be due to its high surface 
activity and pore formation in the cytoplasmic membrane. Nisin can retard the release of 
emulsified drug from oil in water emulsion which might be due to gel formation at oil 
water interface. 159 
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Formulation and In Vitro-In Vivo Evaluation of a New Compression-

Coated Tablet of Amoxicillin/Clavulanate; and Formulation Potential of
 
the Antimicrobial Peptide Nisin 
CONCLUSIONS 
Compression-coated tablet can be used to separate active ingredients in the same 
dosage form. It consists of three layers, and each layer must have good friability  and 
compressibility. Consequently, compression of the outer coat into the hard inner core is 
challenging. Compression-coated tablet formulation was developed for amoxicillin and 
clavulanic acid. Amoxicillin in the outer layer was separated from clavulanic acid in the 
core by inactive ingredients in the middle layer. Stability of clavulanic acid in the core 
was optimized by incorporation of hydrophobic ingredients in the middle layer. Because 
of the formulation design, the dissolution profiles of amoxicillin and clavulanic acid from 
the compression-coated tablet were different from those of the conventional single layer 
tablet. 
The pharmacokinetic parameters of a new compression-coated tablet formulation 
of amoxicillin/clavulanate and  Augmentin®,  a reference product, were evaluated 
employing  a  randomized  balanced  cross  over  study.  Preliminary  statistical 
pharmacokinetic analysis was done for 8 subjects. Data were analyzed by a two one-sided 
t-test.  The two  formulations  were  bioequivalent  for  amoxicillin  for  all  the 
pharmacokinetic parameters. However, the two formulations were not bioequivelent for 
clavulanic acid for AUC and C-max, which might be due to the small number of subjects 
used in the study. 161 
Nisin is a highly surface active cationic polypeptide with antimicrobial activity. It 
can withstand  activity  loss during thermal  processing, and exposure to  acidic 
environments. These characteristics and others, such as non-toxicity and surface activity, 
make its potential as an antimicrobial emulsifier attractive in food and pharmaceutical 
emulsions. The emulsifying activity  of nisin was evaluated using conductivity 
measurements. The results have shown that nisin has high ability to stabilize oil in water 
emulsions in comparison to Tween 80 and 13-casein. The emulsifying activity of nisin is 
highly  concentration  and pH dependent.  It  increases  sharply  with  increasing 
concentration and pH. 
The interfacial tension kinetics of nisin and 13-casein were evaluated at n-
hexadecane-water interface using DuNoUy tensiometer. In order to account for the effect 
of conformational change during adsorption, the interfacial tension kinetic data of each 
protein were analyzed with reference to a two state mechanism that allows for protein to 
adsorb in structurally dissimilar forms. The model has shown that adsorption at high 
concentrations occurs in extended form and at low concentrations in compacted form. 
The model was limited with the assumptions of the same reduction of interfacial tension 
per unit surface area by the two states, and no effect of diffusion on adsorption, which 
might be significant at very low concentrations. 162 
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